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Circadian Integration of Hepatic de novo Lipogenesis and Peripheral Energy 
Substrates Utilization 
 
ABSTRACT 
 
The liver maintains energy substrate homeostasis by synchronizing circadian or 
diurnal expression of metabolic genes with the feeding/fasting state. The activities of 
hepatic de novo lipogenic gene products peak during feeding, converting carbohydrates 
into fats that provide vital energy sources for peripheral tissues. Conversely, 
deregulated hepatic lipid synthesis leads to systemic metabolic dysfunction, establishing 
the importance of temporal regulation of fat synthesis/usage in metabolic homeostasis. 
Pharmacological activation of peroxisome proliferator-activated receptor δ/β (PPARδ/β) 
improves glucose handling and systemic insulin sensitivity. However, the mechanisms 
of hepatic PPARδ actions and the molecular pathways through which it is able to 
modulate global metabolic homeostasis remain unclear. Here we show that hepatic 
PPARδ controls the diurnal expression of lipogenic genes in the dark/feeding cycle. 
Adenovirus mediated liver restricted activation of PPARδ promotes glucose utilization in 
the liver and fat utilization in the muscle. Liver specific deletion of either PPARδ or the 
PPARδ-regulated lipogenic gene acetyl-CoA carboxylase 1 (ACC1) reduces muscle 
fatty acid uptake. Unbiased metabolite profiling identifies 1-stearoyl-2-oleoyl-sn-glycero-
iii
 3-phosphocholine (SOPC) as a serum lipid derived from the hepatic PPARδ-ACC1 
activity that reduces postprandial lipid levels and increases muscle fatty acid uptake. 
These findings reveal a regulatory mechanism that coordinates lipid synthesis and 
utilization in the liver-muscle axis, providing mechanistic insights into the hepatic 
regulation of systemic energy substrates homeostasis.  
iv
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Chapter 1: 
 
INTRODUCTION 
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  Metabolic Flexibility and Metabolic Syndrome 
 
 Metabolic flexibility describes the capacity of human body to switch between 
carbohydrates and lipids as the predominant source of energy substrates [1]. Following 
a meal, the rapid rise in blood glucose is detected by β-cells in the pancreas, which then 
release insulin to promote glucose oxidation in the skeletal muscle and reduce glucose 
production in the liver. At the same time, insulin suppresses free fatty acid release from 
the adipose tissue, making glucose the predominant source of energy substrates during 
feeding. As the action of insulin continues, additional glucose can also be converted to 
glycogen in the liver and skeletal muscle for storage. However, due to the limited 
capacity of glycogen storage, glucose eventually is synthesized into more energy dense 
fatty acids by the liver. These newly synthesized fatty acids, together with the dietary 
lipids are converted into triglycerides and exported in the form of very low density 
lipoproteins (VLDL). VLDL derived fatty acids are taken up by the skeletal muscle as the 
energy source or by the adipose tissue for storage in the post-absorptive phase (Figure 
1.1). Conversely, at the fasted state fatty acids are released from the adipose tissue for 
energy production. In the meantime, partly promoted by the release of glucagon from 
the pancreas, the liver converts stored glycogen, glycerol from lipolysis and amino acids 
into glucose to maintain normal blood glucose level (Figure 1.2).  
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Figure 1.1. Energy substrates utilization under the feeding condition. The dietary source 
of lipids and carbohydrates enter into the circulation following a meal. Liver, muscle and 
adipose tissue coordinately utilize these energy substrates mainly under the control of 
insulin. 
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Figure 1.2. Energy substrates utilization under the fasting condition. At the fasting state, 
diminished blood glucose level reduces circulating insulin concentration. This leads to 
increased lipolysis in the adipose tissue and increased glycogen breakdown in the liver 
and muscle. Additional glucose is generated via gluconeogenesis in the liver to maintain 
blood glucose level. Liver and muscle rely on fatty acids released from the adipose 
tissue as the major substrate for energy production.  
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   Metabolic syndrome is a collection of metabolic disorders that increase the risk of 
developing type II diabetes, cardiovascular diseases and certain types of cancer [2]. At 
the core of metabolic syndrome is the disruption of insulin action, which leads to 
deregulated glucose metabolism in major insulin responsive tissues described above. 
Paradoxically, insulin continues to act on lipid synthesis pathways in the liver while 
failing to curtail the activity of gluconeogenic and lipolytic pathways in the liver and 
adipose tissue, respectively, exacerbating hyperglycemic and hyperlipidemic conditions. 
How insulin action is impeded under obese and diabetic conditions remain a major 
scientific challenge. Recent discoveries have linked insulin resistance with chronic low 
grade inflammation [3], endoplasmic reticulum (ER) stress [4], mitochondria dysfunction 
[5], and oxidative stress [6, 7], likely as a result of over-nutrition.  
 Much of the interest in studying metabolic flexibility stems from the observation 
that obese and/or diabetic human subjects fails to switch to glucose utilization and 
continue to oxidize lipids under a glucose tolerance test or euglycemic insulin clamp [8]. 
Thus the identification of pathways that control metabolic flexibility is key to combating 
the epidemic of metabolic syndrome.  
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  Lipid Signaling and Metabolic Homeostasis 
  
 The seminal work by Randle et al. [9] demonstrated that perfusion of isolated rat 
muscle with free fatty acids was sufficient to suppress glucose uptake and impair insulin 
action in muscle cells, suggesting that fatty acids or their derivatives are able to directly 
influence cellular fuel preference. Later human studies with lipid infusion have confirmed 
the direct role of fatty acids in mediating insulin resistance [10, 11].  
 Western lifestyle imposes significant pressure on the metabolic system. Over-
nutrition causes ectopic accumulation of lipids in metabolic tissues, and is associated 
with the development of insulin resistance [12]. This observation is supported by several 
genetic models in rodents. Overexpression of lipoprotein lipase in the skeletal muscle 
promotes lipid accumulation and muscle insulin resistance [13]. Similarly, adenoviral 
overexpression of CD36, a major fatty acid transporter protein in the liver, increases 
hepatic lipid content and is sufficient to cause hepatic insulin resistance [14].  
Conversely, genetic ablation [15-18] or pharmacological inhibition [19] of factors 
involved in fatty acid transport protects mice from high fat diet (HFD) induced insulin 
resistance. However, fat deposition alone is not sufficient to explain the impaired insulin 
action in these tissues. Human can be obese but free from insulin resistance. 
Endurance training athletes have increased intramuscular lipids but are insulin sensitive 
[20, 21]. Genetic mouse models with enhanced hepatic lipogenesis [22] are protected 
from diet induced insulin resistance at least in the short term. Nevertheless, these 
observations suggest that lipid metabolism is closely involved in the development of 
6
	  insulin resistance and the resulting loss of metabolic flexibility. 
 From early examples of luekotrienes and prostaglandins, to the recent 
identification of bioactive fatty acids [23] and phosphocholines (PCs) [24-26], lipids are 
well-known signal transducers involved in immune regulation [27, 28], oncogenesis [29], 
and neurological processes [30]. When fatty acids are taken up by cells, long chain acyl-
CoA synthetases (ACSLs) immediately attach a CoA moiety to fatty acids [31]. Fatty 
acyl-CoAs serve as the substrate for the synthesis of diacylglycerol (DAG) and 
ceramide, or are used for oxidation in the form of fatty acyl-carnitines. It is thought that 
when lipid load exceeds the metabolic capacity of the body, these lipid metabolites 
accumulate and exert inhibitory effects on insulin actions (Figure 1.3).  
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Figure 1.3. Overview of the lipid signaling pathways that interact with the insulin 
signaling pathway. Key signaling molecules are highlighted in red.  
 
 
 
 
 
 
 
 
8
	  DAG 
 
 DAG is an intermediate metabolite that can be synthesized de novo from fatty 
acids. It can also be generated from the hydrolysis of triglycerides and phospholipids by 
adipocyte-triglyceride lipase (ATGL) and phospholipases, respectively [32]. It has long 
been known to serve as a secondary messenger for the activation of protein kinase C 
(PKC) [33]. A particular group of PKCs, known as novel PKCs requires only DAG for its 
activation [34]. PKC activation highly correlates with insulin resistance in obese animal 
models and is implicated in suppressing insulin action via serine phosphorylation of 
insulin receptor substrate 1 (IRS1) in both muscle and liver [35]. While this molecular 
mechanism has been demonstrated in cell culture models, genetic models of novel PKC 
knockouts give complex phenotypes. For example, PKCθ knockout mice are protected 
from lipid infusion induced muscle insulin resistance [36], but fail to prevent long term 
HFD induced muscle insulin resistance [37]. Additional isoforms of novel PKCs are also 
implicated in promoting metabolic dysfunction under diet induced obesity. However, 
improvements in PKCδ and ε knockout mice are confounded by diminished lipid 
accumulation in the liver [38] or enhanced insulin secretion from the pancreas [39]. 
Collectively, although DAG level is tightly associated with the insulin resistant state, 
whether PKC is the obligatory downstream factor in mediating insulin desensitizing 
effects of DAG is not clear.  
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  Ceramide 
 
 Ceramide is a membrane lipid derived from sphingolipid metabolism [40]. It 
activates protein phosphatase 2A (PP2A) and subsequently inactivates Akt to attenuate 
insulin signaling [41]. In obesity, ceramide concentrations are increased in muscle and 
liver [42]. Blockade of ceramide synthesis by a inhibitor of serine palmitoyl transferases 
1 leads to improved muscle insulin sensitivity in rats infused with saturated fatty acids or 
in Zucker rats, a genetic obese model [42].  
 
Fatty acyl-Carnitines 
 
 Fatty acids oxidation is initiated by fatty acyl-CoAs import into mitochondria via 
carnitine palmitoyltransferases [43]. This step converts fatty acyl-CoAs into fatty acyl-
carnitines. Muscle and serum levels of medium and long chain fatty acyl-carnitines are 
indicators of mitochondria fuel selection under normal physiological conditions [43]. High 
levels of fatty acyl-carnitines in the fasting state correspond to high fatty acid oxidation 
rate. Obese animals have higher fatty acyl-carnitine levels at the fed state, suggesting 
the lack of metabolic switch to glucose oxidation. It also raises the possibility that fatty 
acyl-carnitines antagonize glucose utilization. Although the detailed mechanism is still 
missing, excessive accumulation of fatty acyl-carnitines in the muscle impairs glucose 
oxidation by preventing pyruvate channeling into mitochondria. On the contrary, limiting 
fatty acid entry into mitochondria by deleting malonyl-CoA decarboxylase restores 
10
	  glucose oxidation in obese animals [44].  
 
Membrane Properties 
 
 The concept of lipotoxicity is largely viewed as the consequence of precise 
signaling mechanisms initiated by specific metabolites [45]. What should not be 
overlooked, though, is the impact of lipid loading on very fundamental cellular 
characteristics, such as membrane fluidity and integrity. Saturated fatty acids such as 
palmitate promote insulin resistance in the muscle through c-jun N-terminal kinase 
(JNK) followed by serine phosphorylation of IRS1, whereas monounsaturated fatty acids 
are devoid of such effects [46]. Plasma membrane is partitioned into lipid rafts, within 
which reside signaling proteins. Lipid rafts are poor in detergent solubility due to high 
concentrations of saturated fatty acids, sphingolipids and cholesterol. Incubation of cells 
with saturated fatty acids promotes the aggregation and activation of Src family kinase 
in the lipid rafts, and the induction of JNK phosphorylation [47].  
 Lipidomics profiling of ER membrane comparing lean and obese mice revealed 
significantly increased phosphocholine (PC) to phosphoethanolamine (PE) ratio. 
Maintaining the normal ratio between PC and PE is essential for the integrity of ER 
membrane. In obese conditions, the high PC to PE ratio creates a leaky membrane that 
results in disrupted calcium homeostasis and ER stress, each of which are known to 
impair insulin signaling. Reverting the PC to PE ratio via ablation of 
phosphatidylethanolamine N-methyltransferase (PEMT), a key enzyme in converting PE 
11
	  to PC, restores insulin sensitivity in these mice [48]. 
 
Regulation of Lipid Synthesis 
 
 The regulation of lipid synthesis is part of the program to maintain metabolic 
flexibility. The rate of lipid synthesis from carbohydrates (de novo lipogenesis) is 
critically controlled at several steps by acetyl-CoA carboxylase 1 (ACC1), fatty acid 
synthase (FAS) and stearyl-CoA desaturase 1 (SCD1). Together, these enzymes 
sequentially utilize the acetyl-CoA derived from the glycolytic pathway to synthesize 
saturated or monounsaturated fatty acids [49]. These newly synthesized fatty acids are 
added to the glycerol backbone to form triglycerides (TG), phospholipids and other 
intermediate metabolites. The availability of energy substrates during fasting and 
feeding is a major driving force to regulate lipid synthesis. Circadian clock also 
modulates this process as an additional mechanism to couple lipid synthesis with the 
fasting and feeding cycle.  
 In mammalian cells, the ATP/AMP and NAD+/NADH ratios are major forms of 
energy indicators. Fluctuations of these small molecules are detected by a number of 
highly conserved energy sensors, which in turn dictate a plethora of signaling and 
transcriptional events necessary to maintain the balance between energy supply and 
demand. The AMP-activated protein kinase (AMPK) and NAD+ dependent deacetylase 
Sirtuins [50], such as SIRT1, have emerged as key energy sensors that elicit adaptive 
responses to energy deficit in metabolic tissues under conditions such as caloric 
12
	  restriction (CR), fasting and exercise. Conceivably, these energy-sensing mechanisms 
are actively modulating lipogenesis. A low ATP/AMP ratio triggers the activation of 
AMPK. A number of cellular targets have been identified that mediate the immediate 
effects of AMPK activation. In liver, both acetyl-CoA carboxylase 1 and 2 (ACC1 and 
ACC2), are targets of AMPK [51]. Phosphorylation of ACC1/2 inactivates their 
enzymatic activity shifting hepatic metabolism from biosynthetic pathways to fatty acid 
oxidation. AMPK also regulates the mammalian target of rapamycin complex 1 
(mTORC1) via direct phosphorylation at the regulatory subunit Raptor or at the 
upstream regulatory protein tuberous sclerosis complex protein 2 [52, 53]. In either 
case, AMPK activation turns off the mTORC1 signaling pathway that is involved in 
protein and lipid synthesis. In adipocytes, AMPK phosphorylates hormone sensitive 
lipase (HSL) [54] and adipose triglyceride lipase (ATGL) [55] for the liberation of free 
fatty acids as energy substrates. In adipose tissue, glucose is the source for fatty acid 
synthesis and glycerol-3-phosphate, the building block for triglyceride synthesis. In 
contrast to skeletal muscle, where AMPK promotes glucose uptake, some reports 
suggest that AMPK activation in the adipocytes inhibits glucose uptake [56], consistent 
with its role in preventing energy consuming biosynthesis.  
 The aforementioned nutrient sensing pathways converge at the transcriptional 
level to regulate lipogenic genes. In liver and adipocytes, several transcription factors 
have been identified as key regulators of de novo lipogenesis that are intimately linked 
to hormonal signals, energy sensors, and nutrient flux (Figure 1.4). 
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Figure 1.4. Overview of the regulation of lipid synthesis. During feeding or fasting, 
changes in nutrient flux, hormonal signals, physiological stress and intracellular small 
molecules are sensed by several signaling pathways that converge at key transcription 
factors to control lipid synthesis. Each of these transcription factors detects a subset of 
physiological signals to coordinately modulate the activity of lipogenic pathway.   
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  SREBP 
 
 The sterol regulatory element binding protein 1c (SREBP1c) is recognized as the 
master regulator of de novo lipogenesis. It is capable of activating the entire repertoire 
of lipogenic gene expression in the liver [57]. SREBP1c is mainly thought to be 
responsible for the insulin induced lipogenic program in the liver, especially under the 
condition of diet induced or genetic models of obesity [58].  Insulin activates SREBP1c 
by enhancing its transcription or by promoting the processing of the inactive ER 
membrane bound form to the active nuclear form [59, 60]. However, the detailed 
mechanism through which insulin is able to activate SREBP1c is not clear. A plausible 
link is the mTOR complexes (mTORC1/2) [61]. Constitutive activation of mTOR 
signaling via genetic ablation of its upstream suppressor TSC1/2 complex induces 
SREBP1c processing and induces lipogenic gene expression [62]. SREBP1c integrates 
additional upstream signals to regulate de novo lipogenesis. The SREBP1 promoter 
contains a nuclear receptor LXR response element and the LXR ligand is able to induce 
SREBP1c expression [63]. It has recently been shown that the nuclear receptor co-
activator PGC1β is able to form a complex with SREBP1c and mediate either saturated 
fat or fructose induced lipogenesis [64, 65]. Reduced cellular PC levels resulting from 
choline deficient diet also trigger the processing of SREBP1c and promote nuclear 
translocation of SREBP1c to activate genes involved in PC synthesis and one-carbon 
cycle metabolism [66]. On the other hand, fasting inhibits SREBP1c activity. This is in 
part due to the fall of circulating insulin concentration. In addition, the conserved nutrient 
15
	  sensors Sirt1 and AMPK all have been shown to directly suppress SREBP1c activity by 
deacetylation [67] or phosphorylation [68], respectively. Consumption of a 
polyunsaturated fatty acid (PUFA) rich diet inhibits SREBP1c activity, potentially via 
inhibition of its processing [69]. PUFA are essential fatty acids and it is thought that the 
dampening of de novo lipogenesis by PUFA is necessary to ensure proper composition 
of membrane lipids that are rich in PUFA [70].  
 
ChREBP 
 
 Feeding rodents with a high carbohydrate diet induces hepatic lipogenesis. The 
carbohydrate response element binding protein (ChREBP) was later shown to be 
responsible for this effect [71]. It has been shown that the ChREBP activity is regulated, 
in part, via nuclear translocation. Fasting induced PKA and AMPK activities are able to 
phosphorylate several serine/threonine sites located on the nuclear localization 
sequence, and hence retaining ChREBP in the cytosol during fasting [72, 73]. The 
mechanisms through which glucose is able to regulate ChREBP activity is still lacking. 
One potential mechanism is the pentose shunt intermediate metabolite xylulose-5-
phosphate [72], which activates the protein phosphatase PP2A to remove the 
serine/threonine phosphorylation induced by PKA, permitting ChREBP translocation into 
the nucleus during high carbohydrate feeding in the liver. In addition, a second 
regulatory mechanism, unique to the adipose tissue, was recently uncovered: An N-
terminal truncated isoform of ChREBP (ChREBPβ) is a much more potent activator of 
16
	  lipogenic gene expression. ChREBPβ expression is regulated by the conventional 
isoform of ChREBP (ChREBPα), which is not subject to glucose regulation but is 
thought to directly sense glucose or glucose metabolites [74]. The rationale of this two-
tiered regulation has not been demonstrated experimentally. Perhaps, it allows 
additional signals to prime the lipogenic response to glucose without directly activating it 
in the absence of glucose.  
 
ER Stress and IRE1α-XBP1 
 
 The ER is a major site for protein folding and lipid synthesis. Because of its ability 
to control the synthesis of nutrients in response to external stimuli, ER is considered a 
nutrient sensing organelle. As mentioned above, the PC composition of the ER may be 
critical to activate SREBP1c, linking ER function to lipogenesis [66]. Upon feeding or 
chronic over-nutrition, the elevated biosynthetic requirements for the ER trigger ER 
stress, or the unfolded protein response (UPR). To date, the three branches of UPR 
pathways have all been implicated in the regulation of lipogenesis (Reviewed in [4]). In 
particular, the X-box binding protein 1 (XBP1), downstream of the ER stress sensor 
IRE1α, has been shown to transcriptionally activate genes involved in de novo 
lipogensis such as SCD1 and ACC2 [75]. Recently, IRE1α has been shown to degrade 
lipogenesis and sterol biosynthesis gene mRNA through regulated IRE1-dependent 
decay (RIDD), adding another layer of regulation [76].  
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Circadian Regulators 
 
 The adipose and hepatic lipogenesis programs exhibit a diurnal fluctuation 
corresponding to the feeding behavior in mice. Although the aforementioned 
mechanisms are capable of inducing lipogenic programs as an adaptive response, the 
coupling of cellular circadian clock machinery to lipogenesis may provide benefits to 
maximize cellular responses when substrates are made available. The nuclear receptor 
Rev-erb α and β are core components of mammalian circadian clock [77-79]. The 
expression of Rev-erbα/β maintains a 24-hour cycle and peaks during the day, 
corresponding to the fasting state in mice. Rev-erbα has also been shown as a heme 
sensor [80]. Upon heme or other endogenous ligands binding, a co-repressor complex 
consisting of nuclear receptor co-repressor 1 (NcoR) and histone deacetylase 3 
(HDAC3) is recruited to turn off target gene expression. Genome-wide chromatin-
immunoprecipitation-sequencing (ChIP-seq) of rev-erbα/β, as well as its co-repressors 
NcoR and HDAC3, revealed extensive co-occupancy around lipogenic genes, including 
the master regulator SREBP1c. They were functionally important to suppress the 
hepatic lipogenic program in the day.  
 Lipid products appear to play a role in the feedback regulation of de novo 
lipogenic pathway activities. For example, the lack of endogenous monounsaturated 
fatty acid (MUFA) synthesis via SCD1 deletion in the liver is able to prevent the 
transcriptional activation of the lipogenic program under high carbohydrate diet 
18
	  conditions [81]. The alteration of the ER membrane composition [66] and/or the 
activation of ER stress [82] are likely mechanisms. However, it also raises the possibility 
that additional transcription factors exist to sense the MUFA level in the cell and 
regulate de novo lipogenesis.  
 
Lipogenesis and Metabolic Diseases 
 
 The importance of de novo lipogenesis in maintaining normal cellular functions is 
highlighted by the fact that whole body knockout of ACC1 or FAS is incompatible with 
life [83, 84]. Although de novo lipogenesis is increasingly recognized to play an 
important role in many cell types, such as immune cells and cancer cells, the adipocytes 
and liver are the two predominant sites of de novo lipogenesis in the context of global 
metabolic regulation.  
 
I. Lipid Synthesis in the Adipose Tissue 
 
 De novo lipogenesis in the adipocytes is relatively less studied.  It is quantitively 
less important in ad libitum feeding conditions in mice, but is significantly increased 
during caloric restriction [85]. On the contrary, obese mice have reduced lipogenic gene 
expressions [23]. These observations suggest a potentially beneficial role of adipose de 
novo lipogenesis in metabolic homeostasis. This notion is supported by genetic models 
with increased adipose lipogenesis. For example, adipose tissue specific glucose 
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  transporter Glut4 overexpression increases the entire de novo lipogenic program activity 
through the transcription factor ChREBP and improves systemic insulin sensitivity of 
mice with diet induced obesity [74]. Similarly, the fatty acid binding protein FABP4 (aP2) 
knockout mice have increased de novo lipogenic gene expressions in the adipose tissue 
and are protected from diet induced insulin resistance [17, 18, 23]. The reduced adipose 
inflammation and adipocytokine production, increased adipokine and lipokine secretion 
and decreased free fatty acid release are all proposed to explain the beneficial effects of 
an enhanced adipose lipogenesis program. However, several lines of evidence also 
present a contradicting view that lipogenesis in the adipose tissue is deleterious to 
global metabolic homeostasis. The adipose specific SREBP1c overexpression mice 
developes insulin resistance and lipodystrophy [86]. FAS knockout in the adipose tissue 
is beneficial by promoting a brown fat like phenotype [87]. Similarly, SCD1 adipose 
knockout is protective, in part, by reducing adipose inflammation [88]. These data 
reinforce the idea that intermediate metabolites generated through manipulating 
lipogenic pathways are likely the direct link between lipid metabolism and insulin 
resistance.  
 
II. Lipid Synthesis in the Liver 
 
 In humans, stable isotope tracer studies have estimated the contribution of de 
novo lipogenesis to overall VLDL TG quantities amounts to approximately 5% at the 
fasting state and 18% at the postprandial state [89, 90], whereas in patients with fatty 
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  liver diseases, de novo lipogenesis contributes to roughly 30% of overall VLDL TG 
quantities [91]. Thus hepatic de novo lipogenesis is an importance source contributing 
to dyslipidemia in patients with fatty liver diseases [92]. Indeed, suppression of hepatic 
de novo lipogenesis via genetic knockouts protects mice from a range of deleterious 
outcomes by diet induced or genetic obesity [93, 94]. As mentioned earlier, the 
accumulation of triglyceride per se is not sufficient to cause systemic insulin resistance, 
but rather the intermediate metabolites are likely detrimental. Indeed, a number of 
models with reduced hepatic lipogenesis show a concurrent reduction in hepatic DAG 
level [94, 95]. Paradoxically, short term adenoviral overexpression of key lipogenic 
genes such as ChREBP [96] or acute ablation of repressors of lipogenesis, such as 
HDAC3 [97], improves overall metabolic functions in obese animals. A likely explanation 
is the formation of small lipid droplets, drastically different from HFD induced large lipid 
droplets. These lipid droplets are sequestered from cytosolic kinases, despite containing 
increased DAG [97]. Alternatively, it was shown in drosophila S2 cells that small lipid 
droplets are more readily utilized for oxidation, thereby decreasing the likelihood of 
generating deleterious intermediate metabolites [98]. Of note, the intrinsic short duration 
of gain of function studies makes it difficult to evaluate the long-term outcome of a 
constitutively active lipogenic program. One study shows that liver specific DGAT2 
transgenic mice do not develop insulin resistance despite severe hepatic steatosis 
under standard chow diet [22], while the other study using the same animals observes 
the existence of severe insulin resistance [99]. Recently, liver specific overexpression of 
SREBP1c has also been shown to induce insulin resistance [100]. Taken together, the 
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  dissociation of hepatic steatosis from insulin resistance demonstrates the importance of 
lipid sequestration in preventing insulin resistance. These seemingly contradictory 
results strengthen the notion that intermediate signaling molecules from either lipid 
synthesis or breakdown are likely the direct link between lipid metabolism and tissue 
insulin resistance.  
 Regardless of the site, manipulation of the lipogenic program elicits a global 
change in metabolic homeostasis. As evidenced in the adipose tissue, the systemic 
effects are likely mediated through secreted factors. Notably, a product of lipogenesis, 
palmitoleate was identified as a lipokine, capable of improving muscle insulin sensitivity 
and suppressing hepatic lipogenesis [23]. Metabolomics profiling among adipose tissue, 
liver and serum has revealed a greater extent of similarities between liver and serum 
profiles than between adipose tissue and serum ones [101]. It was found that hepatic 
FAS is required to produce nuclear receptor PPARα ligands in the context of fat free diet 
[26]. Given the minimal contribution of de novo lipogenesis to overall energy substrates, 
this raises the question whether hepatic de novo lipogenesis regulates systemic 
metabolic homeostasis through lipid factors.  
 
Circadian Regulation and Metabolic Flexibility 
 
 The 24 hour cycle of day and night as the earth evolving around its axis provides 
predictability to organisms living on it: the optimal time for photosynthesis and food 
availability. Although metabolic processes can be regulated solely based on adaptive 
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  mechanisms, it would likely require all potential biochemical pathways to be primed for 
activation. Thus such scenario is energetically costly. This leads to the development of 
the circadian clock machinery that incorporates environmental cues, such as the 
light/dark and feeding/fasting cycle, to proactively regulate behavior and physiological 
functions [102, 103].  
 
I. Molecular Architecture of the Circadian Clock 
 
 The hierarchical architecture of the circadian clock maintains a master regulator 
in the suprachiasmatic nucleus (SCN) located below the optical nerve in the 
hypothalamus [102]. It receives photonic signals from the retina and synchronizes daily 
activities and feeding behavior with the light and dark cycle. It also sets the molecular 
timing, or phase of the peripheral clock via neuronal or hormonal signals. 
 At the molecular level, the circadian clock machinery is comprised of several 
feedback loops (Figure 1.5). The core clock consists of a transcriptional activator 
complex formed by the transcription factor Bmal1 and Clock, and a repressor complex 
of Per and Cry genes. The activator complex binds to the E-box elements on Per and 
Cry gene promoters to mediate their transcription, whose protein products together with 
a number of chromatin modifying enzymes negatively regulate Bmal1 and Clock 
activities via direct protein-protein interactions. Upon exceeding a critical threshold, the 
repressor complex prevents further accumulation of Per and Cry proteins. Bmal1 and 
Clock also induce the expression of the nuclear receptor Rev-erbα and β. These two 
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  genes recognize the ROR response elements (RORE) on the Bmal1 promoter and 
compete with transcriptional activator RORs to repress Bmal1 gene expression. Thus 
diminished Bmal1 and Clock activities at the peak of Per and Cry actions remove the 
negative regulation of Bmal1 transcription by Rev-erbα and β. This regulatory logic 
permits the reactivation of the activator complex once Per and Cry proteins are 
degraded (Reviewed in [102, 103]). Post-transcriptional modifications are prevalent in 
the circadian clock system. The degradation of Per proteins is actively regulated by 
caesin kinases. Cry proteins are phosphorylated by AMPK and subsequently targeted 
by E3 ligase FBXL3 [104]. Bmal1 can be SUMOylated [105], phosphorylated [106, 107], 
deacetylated [108] and ADP-ribosylated [109]. Each of these modifications perturbs the 
Bmal1 transcriptional activity. The design of such a system with complex feedback 
loops not only ensures the robustness of the circadian oscillation, but also generates 
multiple expression patterns of circadian clock genes [103]. The latter is important to 
achieve optimized behavioral and physiological outputs at different time of the day.  
Figure 1.5. The molecular architecture of core circadian clock. The feedback loops 
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  (Figure 1.5. Continued) constituted by core clock proteins ensure a self-sustained 
expression cycle over the course of the day. In addition, these core clock proteins 
control a number of metabolic processes so that the metabolic processes are coupled 
with environmental cues such as light/dark and feeding/fasting cycles.  
 
II. Circadian Regulation of Metabolism 
 
 Transcriptional profiling of liver over the course of 48 hours has identified that 2% 
to 15% of the mammalian transcriptome is rhythmically expressed [110-113]. Among 
these rhythmic transcripts are transcription factors and critical enzymes regulating 
cellular energy sensor levels. The expression or activity of roughly 20 nuclear receptors 
[114], transcription factors involved in xenobiotic detoxification pathways [115], UPR 
components [116], the NAD+ salvage pathway [117, 118] and MicroRNAs [119-121] are 
directly under the control of the core clock machinery. Hence the hierarchical 
architecture of the molecular clock makes possible the regulation of a large quantity of 
transcripts, many of which are involved in carbohydrate, lipid and cholesterol 
metabolism.  
 There are long standing interests in understanding the metabolic consequences 
of altered circadian clock due to public health concerns of shift work. The impact of 
disrupted circadian clock on metabolism was first revealed from the Clock mutant mice 
[122]. These mice lack behavioral circadian rhythm and developed insulin resistance on 
HFD. Although the altered neuroendocrine signals and the hyperphagic phenotype in 
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  these mice contribute to the metabolic deterioration, perturbed metabolic pathways in 
metabolic tissues are also likely factors. Disrupted circadian clock has been postulated 
to cause metabolic disorders in two ways: (1) The reduced expression of metabolic 
genes at all time, (2) The shift of metabolic gene expression so that biochemical 
reactions happen at the wrong time. Mouse genetic models so far support the latter 
scenario. Liver specific deletion of Bmal1 results in a hypoglycemic phenotype only 
during the day when the Bmal1 activity is the greatest [123]. In mouse liver, the 
repressor Cry1 and Cry2 protein levels peak around the night to day transition time and 
diminish at day to night transition. They are found to suppress gluconeogenesis at the 
post-absorptive phase (night to day transition). Disruption of Cry1/2 genes leads to a 
hyperglycemic phenotype at night to day transition upon fasting [124, 125]. The effects 
of circadian proteins on glucose metabolism are further validated in human genome-
wide association studies, in which polymorphisms around the Cry2 protein are 
associated with hyperglycemia and type II diabetes [126].  
 Circadian clock genes also play significant roles in lipid metabolism. The role of 
the aforementioned Rev-erbs-NcoR-HDAC3 axis in mediating hepatic de novo 
lipogenesis is a prime example [79]. In addition, Clock mutant mice develop 
hypertriglyceridemia particularly during the day time as a result of abnormal lipoprotein 
production [127]. Both Bmal1 and Per2 are shown to promote the transcription and 
activity of nuclear receptor PPARα [128, 129], although the functional outcomes of these 
pathways have not been examined. Loss of core clock components Cry or Clock impairs 
the rhythm of XBP1 and the response to ER stress induced by tunicamycin in a time 
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  dependent manner [116], resulting in altered lipid metabolism.  
 The coordinated regulation of both glucose and lipid metabolism by peripheral 
circadian clock highlights a fundamental role of circadian clock in modulating metabolic 
flexibility.  
 
III. Reciprocal Control of Circadian Clock through Metabolic Signals 
 
 Despite the important role of SCN clock in setting overall timing, the peripheral 
clock has also developed the ability to sense food derived signals, especially in the liver. 
These local signals play a dominant role in setting the peripheral clock when feeding 
time is in conflict with the light and dark cycle. We have just begun to uncover the 
metabolic signals feeding into the peripheral circadian clock. The AMPK/SIRT1-PGC-
1α-PPARs nutrient sensing pathway has been shown to impose extensive controls over 
circadian clock machinery. SIRT1 and PARP1 deacetylates [108] and acetylates [109] 
the core clock transcription factor Bmal1, respectively, leading to its degradation or 
stabilization. AMPK phosphorylates Cry1, which promotes its degradation in response 
to low glucose or a synthetic activator AICAR [104]. PGC-1α co-activates the ROR 
family of orphan nuclear receptors to stimulate the expression of Bmal1 and Rev-erbs 
[130]. Both PPARα and PPARγ regulate the expression of Bmal1 in the liver [128] and 
vasculature [131], respectively. A large scale RNAi screen of cellular circadian clock 
modulators identified an integral role of the folate synthesis pathway in setting cellular 
clock, although the direct metabolites and genes within the pathway remain elusive. 
27
	  Besides the nutrient sensing pathways, insulin signaling pathway components were also 
enriched in the RNAi screen [132]. A potential mechanistic link is Glycogen Synthease 
Kinase 3 (GSK3). It phosphorylates Bmal1 and alters its protein stability [106]. 
Immunoprecipitation of Bmal1 in fibroblast identified PKCα as a component of the 
activator complex, linking stress signaling directly to circadian clock [133]. The 
importance of metabolic feedback to the circadian clock is revealed by examining the 
circadian rhythm of mice fed a high fat diet [134]. These animals developed aberrant 
feeding behavior, underscoring the interplay between metabolism and circadian rhythm 
in the development of metabolic syndrome. 
 It is worth noting that it takes days for the food derived signals to alter circadian 
clock and hence the metabolic programs associated with it. However, once the new time 
is set, it persists even without food derived signals. The resilience of the peripheral clock 
to change likely offsets the metabolic fluctuation in the events of unexpected food 
availability, while the self-sustained cycling preserves metabolic capacity in anticipation 
of food.  
 
Preview of Thesis Work 
 
 In single cell organisms, nutrient influx and energy sensing mechanisms convey 
the availability of energy substrates and regulate substrates utilization. Multicellular 
organisms have evolved to acquire specializations in cellular functions. The fact that in 
mice and humans, the energy production or biosynthesis organ (liver) is separated from 
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  the energy consumption organ (skeletal muscle) and the energy storage organ (white 
adipose tissue) dictates a system for inter-organ communication in order to achieve 
metabolic flexibility. So far, we know that the coordinated utilization of glucose is 
communicated via Insulin and counter-regulatory hormones, and the information about 
the adipose tissue metabolic state is conveyed through lipokine [23] and adipokines. Yet 
no direct evidence exists linking lipid production in the liver with lipid utilization in the 
muscle. As has been discussed extensively in the previous sections, lipid synthesis in 
the liver produces lipophilic signaling intermediates, suggesting a potential role of lipid 
signaling molecules in inter-organ communication. The circadian clock control of lipid 
metabolism in the liver may provide an additional layer of regulation in muscle fuel 
selection. 
 The overarching goal of the thesis work has been to understand the liver’s role in 
determining metabolic flexibility, specifically with regard to hepatic de novo lipogenesis 
in this process. As discussed above, elevated lipid synthesis in the liver is a hallmark of 
insulin resistance state. However, our understanding of hepatic lipogenesis is 
incomplete and key questions remain to be addressed. In this thesis work, we have 
identified PPARδ as an additional regulator of the hepatic de novo lipogenic pathway 
and defined its role in the circadian regulation of muscle fatty acids utilization.  
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Introduction 
 
 The prevalence of metabolic diseases has increased substantially, partly due to 
rising obesity caused by sedentary life styles and energy surplus. Insulin resistance is at 
the core of these disorders. Excess energy substrates beyond the catabolic or storage 
capacity of the body are believed to cause organelle dysfunction [1]. Elevated non-
esterified free fatty acid has been shown to activate inflammatory response through 
JNK, which suppresses insulin signaling [2-4], while partitioning fatty acid substrates for 
catabolism or triglyceride synthesis prevents high fat diet induced insulin resistance [5, 
6]. Conversely, de novo synthesis of beneficial MUFAs alleviates cellular stress and 
protects against detrimental effects of saturated fatty acids [7]. Therefore, a key step 
towards the development of drugs to treat metabolic diseases is to understand 
mechanisms controlling energy substrate metabolism. In this regard, the liver is one of 
the most important tissues for energy homeostasis known for its role in sustaining 
energy availability through anabolic and catabolic pathways. Hepatic insulin resistance 
results in over-production of glucose and very low-density lipoproteins (VLDL), 
worsening the extent of glucotoxicity and lipotoxicity [1]. Metformin is one of the 
commonly prescribed anti-diabetic drugs that target hepatic glucose output [8]. This 
drug increases the activity of AMPK, an energy sensor that is activated by elevated 
intracellular AMP or AMP/ATP ratio. In the liver, AMPK reduces glucose production by 
suppressing the expression of gluconeogenic enzymes, such as phosphoenolpyruvate 
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carboxykinase (PEPCK) [9]. AMPK also mediates the beneficial effects of adiponectin 
on glucose and lipid metabolism through adiponectin receptors [10, 11].  
 While not a major site for glucose deposition, the liver also plays a role in 
compartmentalizing glucose during feeding [12]. Postprandial hyperglycemia triggers 
insulin secretion, which in turn suppresses gluconeogenesis and at the same time, 
induces hepatic glucokinase (GK) expression [13-15].  Glucose transported into the liver 
through glucose transporter 2 (GLUT2) is phosphorylated by GK to generate glucose-6-
phosphate, which enters metabolic pathways for glycogen synthesis, glycolysis and 
lipogenesis. Genetic manipulations that sustain GK protein levels in the liver have been 
shown to lower blood glucose and improve insulin sensitivity [16-18]. This pathway 
appears to be an alternative approach to control hyperglycemia. However, it is unclear 
whether this process can be pharmacologically activated.   
 The three peroxisome proliferator-activated receptors, PPARα, δ/β and γ, belong to 
the nuclear receptor family. They are activated by dietary fats and are important 
metabolic regulators [19, 20]. PPARα and PPARγ mediate the lipid lowering and insulin 
sensitizing effects of fenofibrates and thiazolidinediones, respectively [21, 22]. PPARα 
reduces circulating triglycerides by up-regulation of fatty acid catabolism in the liver, 
whereas PPARγ increases insulin sensitivity, in part, through directing fatty acid flux into 
storage in adipocytes. PPARδ also shows promise as a drug target to treat metabolic 
diseases [23]. The reported effects of PPARδ activation by systemic ligand 
administration or by transgenic approaches in animal models include correction of 
dyslipidemia and hyperglycemia, prevention of diet-induced obesity, enhancement of 
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insulin sensitivity and modulation of muscle fiber type switching [24-29]. Most of the 
observed beneficial effects are believed to be mediated by increasing fatty acid 
catabolism and mitochondria function in muscle and adipocytes. It is proposed that in 
muscle AMPK activates PPARδ to increase oxidative metabolism and running 
endurance [30].  We and others have recently shown that PPARδ also plays an 
important role in macrophage alternative activation, which exhibits anti-inflammatory 
properties and as such, counteracts the inhibitory effect of inflammatory signaling on 
insulin sensitivity [31, 32].  
 A previous study demonstrated that administration of a synthetic PPARδ agonist, 
GW501516, lowered hyperglycemia in db/db mice by reducing hepatic glucose 
production and increasing glucose disposal [28]. Expression profiling analyses 
suggested that fatty acid oxidation genes were up-regulated in muscle, whereas several 
lipogenic genes were induced in the liver. While the function of PPARδ in muscle fat 
burning is well documented, whether alteration in hepatic gene expression observed in 
systemic drug treatment is a primary or secondary effect has not been addressed.  In 
this study, we sought to determine whether PPARδ has a direct role in hepatic metabolic 
regulation. Our results demonstrated that PPARδ regulates energy substrate utilization 
and limits lipotoxicity in the liver.  
 
Results 
Liver-restricted PPARδ  expression improves glucose homeostasis 
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 To assess potential roles of hepatic PPARδ in the regulation of glucose 
homeostasis, we utilized adenoviral mediated gene delivery to increase PPARδ 
expression/activity in the liver. Previous studies have demonstrated that the over-
expressed PPARδ is active in vivo [33]. A cohort of wild type C57BL/6 male mice were 
fed a high fat diet for 10 weeks to induce insulin resistance, followed by injection with 
adenoviral GFP (control) or PPARδ (adPPARδ) through the tail vein. Adenovirus 
delivered through tail vein is known to concentrate in the liver, which is used commonly 
to achieve liver-restricted expression. Examination of liver sections showed that 
approximately 70% of hepatocytes were infected as determined by GFP expression, 
resulting in a 4- to 5- fold increase in the PPARδ protein level (Figure 2.2A). A series of 
metabolic studies were conducted within a week following the injection. These mice 
were first placed in metabolic cages and the respiratory exchange ratio (RER) was 
examined to determine whether increased hepatic PPARδ altered fuel substrate usage. 
We found a moderate but significant increase in the RER at the resting period in 
adPPARδ mice (Figure 2.1A and Figure 2.3), indicating that PPARδ may increase 
glucose utilization in the liver. In line with this, adPPARδ mice had a lower fasting 
glucose level compared to control animals at the basal state (GFP: 131±7.13; PPARδ: 
109.5±3.15, P<0.05) and throughout the course of glucose tolerance test (GTT) (Figure 
2.1B). Insulin levels measured during GTT showed no significant difference between the 
two groups (data not shown). Insulin tolerance test demonstrated that adPPARδ mice 
had improved insulin sensitivity, supporting the notion that hepatic PPARδ over-
expression enhances glucose handling (Figure 2.1C). To determine how hepatic 
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PPARδ regulates glucose metabolism, liver samples were collected for histological and 
gene expression studies. Interestingly, H & E staining of liver sections revealed signs of 
glycogen and lipids deposition in adenoviral PPARδ infected livers (Figure 2.1D). 
Glycogen and lipids accumulation were further determined by periodic acid-schiff (PAS) 
staining and oil red O staining. After an overnight fast, livers of control mice contained 
minimal glycogen. In contrast, adenoviral PPARδ infected livers showed a substantial 
increase in glycogen positive staining (Figure 2.1D). Similarly, adPPARδ infected livers 
had elevated neutral lipids stains (Figure 2.1D). Quantitative analyses demonstrated 
increased glycogen and triglyceride content in livers of adPPARδ mice, whereas fatty 
acid and cholesterol concentrations remained similar (Figure 2.1D). We did not observe 
significant differences in white adipose tissue (WAT) histology, body weight, the ratio of 
liver or WAT weight to body weight and levels of fasting free fatty acid, triglyceride and 
cholesterol between the two groups, indicating the effects of hepatic PPARδ activation 
on glucose homeostasis were not secondary to changes in other metabolic parameters 
(Table 2.1). Gene expression analysis determined by RT quantitative PCR (qPCR) 
demonstrated that genes involved in glucose uptake and utilization, such as GLUT2, GK 
and pyruvate kinase (PK), were increased in livers of adPPARδ mice compared to 
control animals (Figure 2.1E). Lipogenic genes, including fatty acid synthase (FAS), 
acetyl-CoA carboxylase 1 (ACC1), ACC2 and stearoyl-CoA desaturase 1 (SCD1) were 
up-regulated, most of which have been shown to be induced by systemic ligand 
treatment in livers of db/db mice [28]. Sterol responsive element binding protein 1c 
(SREBP-1c) and PPARγ co-activator-1β (PGC-1β), which has been shown to regulate 
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FAS through co-activation of SREBP-1c, were also induced [34]. In contrast, 
gluconeogenic genes, including PEPCK and HNF4α, were suppressed in PPARδ virus 
infected livers (Figure 2.1E). Levels of PPARα and its targets genes, acyl-CoA oxidase 
(AOX) and carnitine palmitoyl-coA transferase 1 (CPT1) and medium chain acyl-CoA 
dehydrogenase (MCAD) were unaffected, implicating that PPARδ over-expression did 
not cause non-specific, cross-regulation of PPARα pathways. In addition, the 
expression of PPARδ and its target genes was unchanged in other tissues such as 
muscle and WAT (Figure 2.2B). These data suggest that increased hepatic PPARδ 
activity lowers glucose levels in high fat fed mice and implicate a role for PPARδ in 
hepatic metabolic regulation. 
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Figure 2.1. Liver-restricted PPARδ expression improves glucose homeostasis in mice 
fed a high fat diet. A, Adenoviral mediated hepatic PPARδ expression increases the 
respiratory exchange ratio at the resting state. High fat fed C57BL/6 male mice were 
injected with adenoviral GFP or PPARδ through the tail vein. 3 days after viral injection, 
mice (n=5) were placed in metabolic cages to determine the respiratory exchange ratio 
(RER). Mice were 20 weeks old and had been on high fat diet for 10 weeks. Active: 
average RER during the dark cycle; Rest: average RER during the light cycle. B, 
Glucose tolerance test (GTT) and C, insulin tolerance test (ITT) showing improved 
glucose handling and insulin sensitivity in adenoviral PPARδ infected mice compared to 
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(Figure 2.1. continued) control animals (n=7). GTT (overnight fasted) and ITT (6 hours 
fasted) were performed 4 and 5 days after virus injection, respectively. GFP and PPARδ 
indicate mice receiving adenoviral GFP and PPARδ, respectively. D, Histological 
analyses of liver sections (200X) from GFP and PPARδ adenovirus injected mice. Liver 
samples were collected 7 days following virus injection after overnight fast. H&E staining 
was conducted for morphological assessment and PAS staining (counter stained with 
hematoxylin) was performed to identify glycogen, which stained purple. Hepatic 
glycogen and lipid contents were quantified by enzymatic assays. TG: triglyceride; FFA: 
free fatty acid. E, PPARδ regulates the expression of genes in glucose and lipid 
metabolism. Liver samples were harvested from control (GFP) or adPPARδ (PPARδ) 
mice after overnight fast and gene expression was determined by RT qPCR. LDH: 
lactate dehydrogenase; SREBP: SREBP-1c; ChREBP: carbohydrate response element 
binding protein; AOX: acyl-CoA oxidase; CPT1: carnitine palmitoyl-coA transferase 1; 
MCAD: medium chain Acyl-CoA dehydrogenase. *p<0.05. 
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Table 2.1. Metabolic parameters of adenoviral injected C57BL/6 mice 
 Normal Chow High Fat Diet 
Adenovirus GFP PPARδ GFP PPARδ 
Weight (g) 29.38±0.51 30.45±0.82 27.65±1.25 26.91±1.08 
Liver/body weight 0.0856±0.0022 0.0819±0.0016 0.0548±0.0020 0.0555±0.0026 
Fat/body weight N/D N/D 0.0287±0.0047 0.0285±0.0055 
Triglycerides (mg/dL) 53.96±5.42 56.00±3.45 123.55±34.06 115.68±33.41 
Free fatty acid (mmol/L) N/D N/D 0.8779±0.2219 0.9130±0.2680 
Cholesterol (mg/dL) N/D N/D 71.156±5.048 68.448±6.164 
Glucose (mg/dL) 117±3.34 91.75±9.39* 131±7.13 109.5±3.15* 
Insulin (ng/ml) N/D N/D 2.42±0.88 2.34±0.53 
* P<0.05. The normal chow (NC) cohort was 3 months old, while the high fat fed (HF) 
cohort was 18 weeks old (10-week high fat diet challenge, starting at 8 weeks of age). 
The HF cohort lost more weight as mice were put through 3 overnight fasts during the 
one-week experiment period following virus injection. For this reason, the experiments 
for the NC cohort were conducted in 2 weeks. N/D: not determined. 
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 Figure 2.2. Liver-specific PPAR expression through adenoviral gene delivery. A, 
Adenoviral mediated PPARδ expression in the liver. High fat fed C57BL/6 male mice 
were injected with adenoviral GFP or PPARδ through the tail vein. Liver samples were 
harvested 3 days later to determine infection efficiency by GFP signal (lower panel) or 
expression levels by Western blotting (upper panel). B, Gene expression analyses of 
muscle and white adipose tissue (WAT) samples from control (GFP) or PPARδ virus 
injected mice (n=7) by Q-PCR. CPT1: carnitine palmitoyl-coA transferase 1; MCAD: 
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(Figure 2.2. Continued) medium chain acyl-CoA dehydrogenase.Adipon: adiponectin; 
AdipoR1: adiponectin receptor 1. C. Assessment of adenoviral mediated PPARδ 
expression in primary hepatocytes by Western blotting. adPPARδ protein could be 
detected 7 hours after infection and reached the maximal level by 9 hours (26-fold over 
endogenous protein). The effect of AMPK activation could be observed with a 6-fold 
increase in PPARδ protein (8 hours). Lower panel: quantification of Western blot signal 
using ImageJ. D. PPARδ over-expression in primary hepatocytes reduces both basal 
(control) and glucagon-induced glucose production. adGFP or adPPARδ infected 
hepatocytes were incubated ± 10 μg/ml glucagon for 5 hr, followed by the glucose 
production assay for 2 hr. *p<0.05. 
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Figure 2.3. Metabolic cage study and respiratory exchange ratio (RER). High fat fed 
C57BL/6 male mice were injected with adenoviral GFP or PPARδ through the tail vein. 3 
days after viral injection, mice (n=5) were placed in metabolic cages for 2 days. Data 
were collected for the second day over a period of 24 hours to determine the respiratory 
exchange ratio (RER=VCO2/VO2). Active: RER during the dark cycle; Rest: RER during 
the light cycle. 
 
 
 
 
 
 
 
 
 3 
 
 
 
Supplemental Figure 2. Metabolic cage study and respiratory exchange ratio (RER). High fat 
fed C57BL/6 mal  mice were injected with adenoviral GFP or PPARδ through the tail vein. 3 
days after viral injection, mice (n=5) were placed in metabolic cages for 2 days. Data were 
collected for the second day over a period of 24 hours to determine the respiratory exchange ratio 
(RER=VCO2/VO2). Active: RER during the dark cycle; Rest: RER during the light cycle.  
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PPARδ regulates hepatic glucose utilization 
 
The liver utilizes excess glucose for glycogen and lipid synthesis during feeding. To 
further probe the function of PPARδ activation in the liver at the fed state without the 
effects contributed by the high fat diet, adenoviral mediated PPARδ expression was 
conducted in a cohort of 3 months old, lean C57BL/6 mice and liver samples were 
collected under ad libitum feeding condition. Histological and quantitative studies 
demonstrated that increased glycogen and triglyceride contents were also evident in 
livers of chow fed adPPARδ mice (Figure 2.4A and 2.4B). In concert, we found elevated 
protein levels of glycogen synthase (GS) and ACC (Figure 2.4C). Under ad libitum 
feeding, only PK, ACC1 and SCD1 were significantly induced in adPPARδ livers (Figure 
2.4D), which was not unexpected, as genes such as GK and PEPCK are also regulated 
by insulin at the fed state. Hepatic PPARδ expression also reduced fasting glucose 
levels in these animals (GFP: 117±3.34; PPARδ: 91.75±9.39, P<0.05, Table 2.1). 
However, chow fed control and adPPARδ mice performed similarly in GTT and ITT and 
there was no statistical difference in feeding glucose or triglyceride concentrations (data 
not shown). To determine whether the modulation of hepatic glucose metabolism is cell 
autonomous, we performed metabolic tracer studies in isolated primary hepatocytes. 
GFP or PPARδ virus infected hepatocytes were labeled with 14C-glucose to trace 
glucose utilization for glycogen synthesis and oxidation as well as lipogenesis without or 
with insulin stimulation. Insulin-stimulated 14C-glucose incorporation into glycogen 
(Figure 2.5A) and fatty acids (Figure 2.5B) were increased in adenoviral PPARδ 
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infected hepatocytes. In addition, insulin stimulated glucose oxidation determined by 
14CO2 production was also enhanced in these cells (Figure 2.5C), whereas basal fatty 
acid β-oxidation was reduced (Figure 2.5D). The increased glucose oxidation and 
decreased fatty acid catabolism is consistent with the RER result (Figure 2.1A). PPARδ 
over-expression in hepatocytes increased the expression of GK, GLUT2, FAS, ACC1 
and PGC-1β (Figure 2.5E). To validate gene regulation by endogenous PPARδ and 
determine immediate targets, we treated primary hepatocytes from wild type or PPARδ-
/- livers with a PPARδ ligand, GW501516, for 6 hours and found that ACC1, SCD1 and 
PGC-1β were up-regulated in a PPARδ-dependent manner, while GK, GLUT2 and FAS 
were unchanged (Figure 2.5F and data not shown). These data suggest that PPARδ 
over-expression is sufficient to drive target gene expression, likely due to the presence 
of endogenous ligands. In addition, PPARδ activation enhances hepatic glucose 
utilization through direct and indirect transcription regulation. 
 
 
 
 
 
 
57
  
 
 
 
 
 
 
 
 
Figure 2.4. Assessment of the effect of hepatic PPARδ expression on glycogen 
synthesis and lipogenesis in chow fed mice. A and B, Histological, glycogen and lipid 
analyses of liver samples from GFP and PPARδ adenovirus injected mice on a chow 
diet. Liver samples were collected from ad libitum fed animals 2 weeks following virus 
injection. H&E and PAS (counter stained with hematoxylin) staining (A) as well as 
enzymatic assays (B) were conducted to determine glycogen and triglyceride (TG) 
content. C, Levels of liver glycogen synthase (GS) and acetyl co-A carboxylase (ACC) 
determined by Western blotting. Samples were collected from 4 individual animals from 
GFP and PPARδ adenovirus injected mice. Actin was included as the loading control. D, 
Hepatic gene expression determined by RT qPCR. Liver samples were harvested from 
control (GFP) or adPPARδ (PPARδ) mice under ad libitum feeding condition.*p<0.05. 
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Figure 2.5. PPARδ increases glucose utilization in primary hepatocytes. A-C, PPARδ 
increases glucose flux to glycogen synthesis, lipogenesis and glycolysis determined by 
radioactive tracers. Hepatocytes infected with GFP or PPARδ virus were labeled with 
14C-glucose without or with 100 nM insulin. The conversion of radioactive glucose to 
glycogen, fatty acid and CO2 (to estimate glycolysis) was determined and normalized to 
protein content. D, Fatty acid β-oxidation assay determined by 3H-palmitate. E, The 
expression of glucokinase (GK), GLUT2 and and lipogenic genes is up-regulated in 
hepatocytes infected with adenoviral PPARδ. Gene expression was determined by RT 
qPCR 48 hours post-infection. F, Assessment of target gene regulation by endogenous 
PPARδ. Primary hepatocytes from wild type (wt) and liver-specific PPARδ-/- (ko) mice 
were given 0.1 µM GW501516 for 6 hours and gene expression was examined by RT 
qPCR. *p<0.05. 
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PPARδ  increases monounsaturated fatty acid pools 
 
 Fatty acids have been shown to serve as signaling molecules, which could exert 
beneficial (e.g., lipokines) or detrimental (e.g., lipotoxicity) metabolic outcomes [1, 7]. To 
examine the effect of PPARδ regulated lipogenic program on lipid compositions, hepatic 
fatty acids/triglycerides were analyzed. adPPARδ livers contained less saturated fatty 
acids, notably C16:0, in both normal chow and high fat fed cohorts (Figure 2.6A and 
2.6B). In contrast, the concentration of C18:1 (oleic acid) was increased. In addition, the 
ratios of MUFAs to saturated fatty acids were increased in livers expressing PPARδ. 
Previous work has demonstrated that C18 MUFAs are strong activators of PPARδ [35]. 
Indeed, lipid extracts from adPPARδ livers exerted a stronger PPARδ-activating activity 
than control lipids (Figure 2.7A). SCD1 catalyzes the conversion of saturated fatty acids 
to unsaturated fatty acids. We found that the activity of a 5.3 kb mouse SCD1 promoter 
could be induced by PPARδ activation and this effect was lost in the proximal 1.5 kb 
promoter region (Figure 2.6C). This result was consistent with the up-regulation of 
SCD1 in adPPARδ livers. To determine whether the enhanced lipogenesis led to an 
increase in VLDL production, circulating triglyceride concentrations were determined 
after administration of a lipoprotein lipase inhibitor, Triton WR1339, in control and 
adPPARδ mice. There was no difference in the rate of TG release by the liver between 
the two groups (Figure 2.6D), indicating that PPARδ does not affect the steady state 
VLDL-triglyceride production. 
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 Figure 2.6. Increased monounsaturated to saturated fatty acid ratios in adPPARδ livers. 
A and B, Triglycderides were isolated from GFP or PPARδ adenovirus infected livers of 
normal chow (NC) or high fat diet (HF) fed mice. Fatty acid compositions in triglycerides 
were determined by gas-liquid chromatography. The ratios of monounsaturated to 
saturated fatty acids were shown in the tables. C, PPARδ regulates SCD1 promoter. 
Luciferase reporters driven by 5.3 kb or 1.5kb mouse SCD1 promoter were co-
transfected with expression vectors for PPARδ/RXRα into HepG2 cells, together with a 
β-galactosidase reporter internal control ± GW501516 (0.1 µM, PPARδ agonist) for 24 
hours. The reporter luciferase activity was normalized to β-galactosidase activity to 
obtain relative luciferase unit (RLU). D. Triglyceride (TG) production determined by 
administration of a lipoprotein lipase inhibitor, Triton WR1339. Serum TG concentrations 
were measured at the indicated time course after Triton injection. *p<0.05. 
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Figure 2.7. Differential PPARδ and PPARα activities in the liver. A, PPARδ facilitates 
the production of lipid ligands. Primary hepatocytes were transfected with a luciferase 
reporter driven by sv40 promoter containing Gal4 binding sites (4 copies), expression 
vectors for Gal4 (Gal4 DNA binding domain), Gal4-PPARδLBD (Gal4DBD-PPARδ 
ligand binding domain), Gal4-PPARαLBD (ligand binding domain) or Gal4-PPARα LBD, 
together with a renilla luciferase internal control. Lipids were extracted from GFP (empty 
bars) or PPARδ (black bars) adenovirus infected livers from the normal chow cohort. 
~50 μM triglycerides (BSA bound) were given to transfected primary hepatocytes 
cultured in lipoprotein deficient FBS + 4 μg/ml lipoprotein lipase (to release fatty acids) 
for 24 hours. B, Functional interaction between PPARδ/PGC-1β and PPARα/PGC-1α 
on a PPRE-containing heterologous promoter. A luciferase report driven by tk promoter 
with 3-copy PPREs was co-transfected with combinations of expression vectors for 
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Supplemental Figure 4. Differential PPARδ  and PPARα  activities in the liver. A, PPARδ 
facilitates the production of lipid ligands. Primary hepatocytes were transfected with a luciferase 
reporter driven by sv40 promoter containing Gal4 binding sites (4 copies), expression vectors for 
Gal4 (Gal4 DNA binding domain), Gal4-PPARδLBD (Gal4DBD-PPARδ ligand binding 
domain), Gal4-PPARαLBD (ligand binding domain) or Gal4-PPARγLBD, together with a renilla 
luciferase internal control. Lipids were extracted from GFP (empty bars) or PPARδ (black bar ) 
adenovirus infected livers from the normal chow cohort. ~50 µM triglycerides (BSA bound) were 
given to transfected primary hepatocytes cultured in lipoprotein deficient FBS + 4 µg/ml 
lipoprotein lipase (to release fatty acids) for 24 hours. B, Functional interaction between 
PPARδ/PGC-1β and PPARα/PGC-1α on a PPRE-containing heterologous promoter. A luciferase 
report driven by tk promoter with 3-copy PPREs was co-transfected with combinations of 
expression vectors for PPARδ/RXRα, PGC-1β and PGC-1α into HepG2 cells, together with a β-
galactosidase reporter internal control ± GW501516 (0.1 µM, PPARδ agonist) or GW7647 (0.1 
µM, PPARα agonist) for 24 hours. The luciferase activity was normalized to β-galactosidase 
activity to obtain relative luciferase unit (RLU). 
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(Figure 2.7. Continued) PPARδ/RXRα, PGC-1β and PGC-1α into HepG2 cells, 
together with a β- galactosidase reporter internal control ± GW501516 (0.1 μM, PPARδ 
agonist) or GW7647 (0.1 μM, PPARα agonist) for 24 hours. The luciferase activity was 
normalized to β-galactosidase activity to obtain relative luciferase unit (RLU). 
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Transcriptional regulation of hepatic gene expression by PPARδ  
 
 PGC-1β has been shown to be induced by fatty acids and regulate certain 
lipogenic genes by serving as a co-activator for SREBP-1c [34]. Up-regulation of PGC-
1β in adPPARδ livers is expected to increase lipid synthesis. To investigate the 
molecular mechanism through which PPARδ regulates hepatic gene expression and the 
potential involvement of PGC-1β in this process, reporters driven by promoters of 
potential target genes were constructed and their activities were examined in HepG2 
cells by transient transfection assays. The activities of both 2 kb and 0.3 kb mouse GK 
promoters could be induced by PPARδ and RXRα co-transfection, which were further 
enhanced by PGC-1β (Figure 2.8A and 2.8B). Ligand activation had additional effects 
only in the presence of PGC-1β. PPARδ/RXRα up-regulated human ACC2 promoter I in 
a ligand-dependent manner, as described previously [28] (Figure 2.8E). Similarly, this 
ligand activity was substantially amplified by PGC-1β co-activation. In contrast, PPARδ 
had no effect on 1.3 kb human ACC2 promoter II and 3kb mouse FAS promoter, both of 
which are known SREBP-1c targets [36]. PGC-1β was able to increase SREBP-1c 
activities on these gene promoters (Figure 2.8C and 2.8D). PGC-1α has also been 
shown to co-activate PPARδ, particularly in muscle. Unexpectedly, PGC-1α co-
transfection reduced PPARδ effects on ACC2 promoter I (Figure 2.8E, left panel). In 
contrast, it strongly potentiated PPARα activation of MCAD promoter (Figure 2.8E, right 
panel). The preferential functional interaction of PPARδ/PGC-1β and PPARα/PGC-1α 
could also be observed using a reporter containing 3 copies of AOX PPRE (Figure 
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2.7B). Collectively, these data suggest that PGC-1β is a co-activator of PPARδ in the 
liver and support the notion that PPARδ regulates hepatic gene expression through 
direct and indirect mechanisms. 
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Figure 2.8. Direct and indirect transcriptional mechanisms by PPARδ in the control of 
hepatic gene expression. A-E, promoter analyses to determine PPARδ direct target 
genes. Promoter regions of potential target genes were cloned into a luciferase reporter. 
The resulting constructs were co-transfected with combinations of expression vectors 
for PPARδ/RXRα, SREBP-1c, PGC-1β and PGC-1α (for E only) into HepG2 cells, 
together with a β-galactosidase reporter internal control. PPARδ/RXRα transfected cells 
were cultured in the presence or absence of GW501516 (0.1 µM, PPARδ agonist) for 24 
hours. The reporter luciferase activity was normalized to β-galactosidase activity to 
obtain relative luciferase unit (RLU). mGK-2kb: mouse GK 2 kb promoter; hACC2-PI 
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(Figure 2.8. Continued) and PII: human ACC2 promoter I and II; mFAS: mouse FAS 
promoter; mMCAD: mouse MCAD promoter. 
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adPPARδ  mice are protected from lipotoxicity 
 
 The induced lipogenic program in adPPARδ mice raised the concern whether 
increased lipid deposition caused hepatic pathology. Liver damage was assessed by 
serum levels of liver alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST), which leak out to the circulation with liver injury. Intriguingly, both ALT and AST 
were reduced in adPPARδ mice (Figure 2.9A). Consistent with this finding, the activity 
of the stress signaling JNK, determined by the level of phospho-JNK, was reduced in 
adPPARδ livers, whereas that of phospho-Erk, another member of the mitogen-
activated protein kinase, was not affected (Figure 2.9B). These results indicate that 
PPARδ may reduce lipotoxicity thereby improving metabolic homeostasis. In fact, when 
treated with albumin-bound palmitic acid (C16:0), PPARδ adenovirus infected 
hepatocytes had lower JNK phosphorylation and higher insulin-stimulated Akt 
phosphorylation, compared to control cells (Figure 2.9C). There was an increase in 
triglyceride accumulation in adPPARδ hepatocytes (Figure 2.9C). Free fatty acids have 
also been shown to induce chronic inflammation [2]. We therefore examined the 
expression of genes in inflammatory response and found that pro-inflammatory 
cytokines/chemokines, including IL-1β, TNFα, IFNγ and MCP-1 were all down-regulated 
in adPPARδ livers, compared to GFP infected livers from chow fed mice (Figure 2.9D). 
The expression of F4/80, a pan-macrophage marker, was also reduced. In contrast, 
markers for anti-inflammatory, alternative macrophage activation [37], such as Mgl1 and 
MRC1, were up-regulated in adPPARδ livers. The difference in inflammatory gene 
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expression was less evident in the high fat fed cohort, although there was a trend 
toward a reduction in TNFα (p=0.08) and IFNγ in adPPARδ livers. These results indicate 
that PPARδ-controlled lipogenic program may protect the liver against lipotoxicity. 
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Figure 2.9. Reduced stress signaling and inflammatory gene expression in the liver of 
adPPARδ mice. A, Assessment of liver damage in GFP or PPARδ adenovirus infected 
mice on normal chow (NC) or high fat diet (HF) diets by serum AST and ALT activities. 
B, Western blot analyses demonstrating decreased JNK activity in livers of adPPARδ 
mice. Liver lysates were harvested from 4 individual mice/group of the high fat fed 
cohort. p-JNK: phospho-JNK; t-JNK: total JNK; p-Erk1/2: phospho-Erk1/2. C, PPARδ 
inhibits phospho-JNK and increases insulin-stimulated phospho-Akt in primary 
hepatocytes. Hepatocytes were infected with GFP or PPARδ virus for 24 hours in 
William’s E, 5% FBS. Cells were washed and maintained in the same medium ± 100 µM 
palmitate (albumin-bound) overnight. Hepatocytes were serum starved for 2 hours, 
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(Figure 2.9. Continued) followed by insulin stimulation (100 nM) for 30 min. Left panel: 
JNK and Akt signaling was determined by Western blotting in GFP or PPARδ 
adenovirus infected heaptocytes without (control) or with fatty acid treatment (FA 
loading). Right panel: normalized cellular triglyceride content. D, PPARδ suppresses the 
expression of pro-inflammatory genes. Liver samples were harvested from control 
(GFP) or adPPARδ (PPARδ) mice on normal chow (NC) or high fat (HF) diets and gene 
expression was determined by RT qPCR. *p<0.05. 
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PPARδ  activates AMPK in the liver 
 
 As mentioned earlier, AMPK plays a major role in reducing glucose production and 
has been linked to PPARδ activity [30]. Expression analyses showed that PPARδ 
suppressed genes encoding gluconeogenesis (Figure 2.1E). We sought to determine 
whether the activity of PPARδ in increasing glycogen storage (which decreases energy 
substrate availability) and lipogenesis (which consumes energy) might alter the 
energetic status thereby exerting a secondary effect on AMPK activation. Western blot 
analyses demonstrated that levels of phospho-AMPK, which is indicative of AMPK 
activity, were higher in liver lysates of adPPARδ mice (Figure 2.10A). It is known that 
AMPK can be activated by raising AMP coupled with falling ATP or by adiponectin 
signaling. To determine whether the increased AMPK activation was accompanied by 
changes in AMP and/or ATP levels, liver adenine nucleotide concentrations were 
measured by HPLC (Figure 2.10B). Consistent with the increase in AMPK activity, 
levels of ATP were decreased (p<0.05) and AMP were increased (p=0.08) in livers of 
adPPARδ mice compared to those of control animals. ADP and total adenine nucleotide 
remained unchanged. Interestingly, we also found that adPPARδ livers expressed 
higher levels of adiponectin receptor 2 (adipoR2), which activates AMPK through the 
adiponectin signaling pathway [10, 11] (Figure 2.10C). We did not detect any difference 
in circulating adiponectin concentrations (Figure 2.10D), suggesting that PPARδ may 
increase the response to adiponectin through up-regulation of adipoR2 in the liver. To 
further demonstrate the increased AMPK activity was mediated by hepatic PPARδ 
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expression, AMPK phosphorylation was examined in primary hepatocytes infected with 
GFP or PPARδ adenovirus. The level of phospho-AMPK was higher in adenoviral 
PPARδ infected hepatocytes (Figure 2.10E). Furthermore, metformin-induced AMPK 
activation was further enhanced in these cells, compared to GFP infected hepatocytes 
(Figure 2.10F). To probe whether PPARδ-mediated AMPK activation modulates glucose 
metabolism, glucose production was assessed in isolated hepatocytes. The basal 
glucose production rate was lower in adenoviral PPARδ infected hepatocytes compared 
to GFP infected cells (Figure 2.10G). A similar suppressive effect of adPPARδ was 
observed in glucagon-stimulated gluconeogenesis (Figure 2.2D). The ability of 
adPPARδ to inhibit basal glucose production was abolished by addition of compound C, 
an AMPK inhibitor (Figure 2.10G), supporting the hypothesis that PPARδ could 
indirectly activate AMPK through limiting substrate availability, which contributes to the 
glucose lowering effect of PPARδ. 
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Figure 2.10. Increased hepatic AMPK activity in adPPARδ mice. A, Western blot 
analyses showing increased phospho-AMPK (p-AMPK, Thr-172) in adPPARδ livers. 
Liver lysates were collected from 4 individual GFP or adPPARδ mice. B, Adenine 
nucleotide concentrations of liver lysates from control or adPPARδ mice (n=4) 
determined by HPLC assays. *p<0.05; ✝p=0.08. C, RT qPCR analyses demonstrating 
up-regulation of adiponectin receptor 2 (AdipoR2) in adPPARδ livers. The difference in 
adiponectin receptor 1 (AdipoR1) expression was not significant. D, Circulating 
adiponectin concentrations in control (GFP) and adPPARδ mice determined by ELISA. 
E and F, PPARδ expression increases AMPK phosphorylation. Hepatocytes were 
infected with GFP or PPARδ virus for 24 hours in William’s E, 5% FBS. Cells were 
washed and cultured in DMEM for 2 hours. In E, hepatocytes were incubated in DMEM 
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(Figure 2.10. Continued) for 4 more hours before harvesting. Results from two 
representative samples were shown. In F, hepatocytes were treated with metformin 
(met, 2 mM) and harvested at different time points. The basal phospho-AMPK was 
higher at 6-hour (E) than 3-hour (F, minus metformin) after replacing medium to DMEM 
in PPARδ expressing hepatocytes. G, PPARδ reduces glucose production through 
AMPK activation in primary hepatocytes. Hepatocytes were treated as described above. 
Cells were then cultured in glucose free DMEM containing 1 mM pyruvate and 10 mM 
lactate, without or with 20 µM compound C (AMPKi: AMPK inhibitor) or 2 mM metformin 
(AMPK activator) for 2 hours. Supernatant was collected to determine glucose 
concentration. Metformin was included as a control for AMPK mediated suppression of 
glucose production. *p<0.05. 
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 Discussion 
 
PPARδ is known for its role in regulating oxidative metabolism, particularly in the 
muscle [27, 30]. Previous studies have demonstrated that pharmacological activation of 
PPARδ lowered glucose level and reduced hepatic glucose production [25, 28]. 
However, whether the liver is a major site of PPARδ action has not been explored. In 
this study, we employ adenoviral mediated gene delivery to target PPARδ to the liver 
and show that PPARδ regulates glucose utilization for glycogen synthesis and 
lipogenesis, resulting in a secondary effect of AMPK activation. The combined actions 
effectively lower glucose levels in both chow and high fat fed mice. The lipogenic activity 
of PPARδ increases the production of MUFAs, which are activators of PPARδ, and may 
protect the liver from free fatty acid-mediated lipotoxicity and inflammatory response. 
The current work unveils a function for PPARδ in the control of hepatic energy substrate 
homeostasis.  
In response to substrate abundance, such as at the fed state, glucose is stored as 
glycogen and to a lesser extent, used for fatty acid synthesis in the liver. GK plays an 
important role in this process, since glucose entering the liver through GLUT2 is first 
phosphorylated by GK. The resulting product, glucose 6-phosphate, can then be utilized 
for glycogen synthesis, glycolysis and lipogenesis [13]. The level of GK is normally low 
during fasting and induced by feeding. Previous studies showed that hepatic GK over-
expression increased glucose flux into glycogen synthesis, glucose oxidation and 
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lipogenesis, resulting in lowered glucose levels [16-18]. This suggests that in addition to 
regulating glucose production, the liver has the capacity to modulate glycemia through 
glucose utilization mechanisms. Interestingly, many of the effects observed in adPPARδ 
mice mimic adenoviral GK over-expression [18], including reduced fasting glucose 
concentrations and increased hepatic glucose utilization (glycogen storage, glycolysis 
and lipogenesis). Therefore, the glucose lowering effect of adPPARδ is in part driven by 
increased glucose usage through GK up-regulation and de novo lipogenesis 
independent of insulin concentrations, although the insulin action on glucose utilization 
is likely amplified in adPPARδ mice. Our data show that increased hepatic PPARδ 
expression sustains GK levels leading to glycogen accumulation even after overnight 
fast. PPARδ also up-regulates fatty acid synthesis program as well as the lipogenic 
transcription factor and co-activator, SREBP-1c and PGC-1β, resulting in increased lipid 
content. There is no significant difference in the expression of GK and some lipogenic 
genes between ad libitum fed adPPARδ and control mice. Of note, the gene expression 
pattern at the fed state could be confounded by the timing of eating of individual animals 
before tissue collection. Nevertheless, glucose tracer experiments in primary 
hepatocytes support the hypothesis that PPARδ regulates glucose utilization, as evident 
from increased radioactive tracers in glycogen, fatty acid and CO2, the product of 
glycolysis. This functional outcome is mediated by direct and indirect transcriptional 
mechanisms. Promoter analyses suggest that PGC-1β co-activates PPARδ to increase 
ACC2 promoter I activity, while PGC-1β/SREBP-1c up-regulate the activities of reports 
driven by FAS and ACC promoter II. The regulation of GK is more complex. PPARδ 
77
expression up-regulated GK in a ligand-independent manner. However, PGC-1β is able 
to increase PPARδ-controlled GK promoter activity in the absence and presence of 
ligand. It is unclear how PPARδ induces PGC-1β and SREBP-1c. The increased fatty 
acid production may lead to PGC-1β up-regulation [34]. Although PGC-1α has also 
been shown to co-activate PPARδ, our data suggest a preferential interaction between 
PPARδ/PGC-1β and PPARα/PGC-1α in the liver, which may explain the functional 
difference in fatty acid synthesis and oxidation, respectively. Previous work has 
demonstrated that the expression of PPARδ is up-regulation at the dark cycle, whereas 
PPARα is induced at the light cycle [38]. It appears that the specificity of these two 
closely related receptors is determined by their temporal expression and co-factor 
interaction. 
The lipogenic activity of PPARδ raises the concern whether PPARδ activation is 
associated with steatosis or steatohepatitis. Interestingly, adPPARδ mice either on 
normal chow or high fat diet seem to have improved liver integrity determined by serum 
ALT and AST assays. The stress signaling JNK and inflammatory markers are also 
suppressed in adPPARδ livers. Free fatty acids are known to cause lipotoxicity, 
including induction of inflammatory response [2]. It is possible that by partitioning fatty 
acids for triglyceride synthesis, PPARδ activation protects the liver from free fatty acid-
mediated damage. In fact, adenoviral mediated PPARδ expression in primary 
hepatocytes suppresses fatty acid-induced JNK activation and at the same time, 
increases insulin stimulated Akt phosphorylation, which is consistent with the improved 
ITT in high fat fed adPPARδ mice. In addition, certain MUFAs, such as C16:1n7 
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(palmitoleate) and C18:1n7 (oleic acid), have been shown to alleviate endoplasmic 
reticulum (ER) stress induced by saturated fatty acids and improve metabolic 
homeostasis [7, 39]. These MUFAs are immediate products of SCD1 [40, 41]. We find 
that adPPARδ livers contain more MUFAs and less saturated fatty acids on both chow 
and high fat diets, which is accompanied by increased SCD1 expression.  Therefore, 
PPARδ may function to direct free fatty acid for storage and/or to convert toxic lipids to 
less toxic or even beneficial lipid species, thereby protecting livers from lipotoxicity. 
Additional work will be required to determine the role of SCD1 in mediating the 
protective effect. 
PPARδ has been linked to AMPK activation [30]. The underlying mechanism 
remains elusive. AMPK has been shown to suppress lipogenesis and glycogen 
synthesis [10, 42]. At the first glance, it seems paradoxical that PPARδ-expressing livers 
have more glycogen and lipid accumulation and at the same time show increased 
AMPK activity. Our data suggest that PPARδ limits substrate availability through the 
control of glucose utilization for glycogen store and lipogenesis, which consumes 
energy. Together with reduced β-oxidation, these changes lead to lowered 
ATP/increased AMP and a secondary effect of AMPK activation, which further 
contributes to the glucose lowering effect observed in adPPARδ mice. In support of this 
notion, PPARδ expression in primary hepatocytes increases the level of phospho-
AMPK. Inhibition of AMPK activity reverts the effect of reduced basal glucose production 
in adenoviral PPARδ infected hepatocytes. In addition, we observed increased AdipoR2 
expression in adPPARδ livers, which could mediate adiponectin signaling thereby 
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increasing AMPK activity. Therefore, AMPK activation may serve as a feedback 
mechanism and explain why long-term PPARδ ligand treatment does not cause severe 
hepatic lipid accumulation [25, 27]. Of note, although adenoviral mediated over-
expression has been useful for identifying hepatic functions for several metabolic 
regulators [43, 44], whether pharmacological activation of PPARδ could activate AMPK 
to the same extent as acute activation described in the current study remains to be 
determined. 
Immune cells and inflammatory response have emerged as integral components of 
metabolic diseases [45]. JNK, a major pro-inflammatory signaling molecule, 
phosphorylates insulin receptor substrate-1 (IRS-1) and prevents insulin-mediated 
activation of phosphatidylinositol 3-kinase and its downstream effector Akt [2, 4]. The 
current work demonstrates that PPARδ suppresses inflammation in the liver. It has been 
demonstrated that oleic acid (C18:1) or synthetic ligands activate macrophage PPARδ 
to turn on anti-inflammatory, alternative activation [31, 32]. It is possible that hepatic 
PPARδ produces lipid lignads (MUFAs), which in turn activate macrophage (or Kupffer 
cells in the liver) PPARδ to modulate immune response. In fact, the expression of pro-
inflammatory markers, such as TNFα and IFNγ, is down-regulated, while alternative 
activation markers, such as Mgl1 and MRC1, are induced in chow fed adPPARδ livers. 
The reduction in pro-inflammatory gene expression is less evident on high fat diet, likely 
due to the fact that high fat feeding also induces a strong inflammatory response in non-
hepatic cells (e.g., immune cells) [44, 46]. These observations indicate that PPARδ 
functions as a nuclear sensor of dietary fats capable of modulating immune response 
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through regulation of metabolic programs. Despite the potential beneficial effects 
identified in this work, since fatty liver is often associated with type 2 diabetes, the use 
of PPARδ agonists to improve glucose handling may worsen the condition of steatosis. 
Nevertheless, results from the current study provide valuable information for designing 
drugs that target PPARδ for treating metabolic diseases.  
 
Materials and Methods 
Animal experiments 
 
C57BL/6 mice (14 age matched, 8 weeks old males from the Jackson 
Laboratory) were challenged with a high-fat, high-carbohydrate diet (F3282, Bio-Serv, 
Frenchtown, NJ) for 10 weeks. They were then transduced with purified adenovirus via 
tail vein injection (n=7 for both GFP and PPARδ adenovirus). Adenoviral expression 
cassettes were constructed in the pShuttle-IRES-hrGFP vector and amplified in AD293 
cells (Stratagene, La Jolla, CA). 100 µl of 5 x 1010 pfu/ml virus was injected into each 
mouse. Liver-specific PPARδ-/- mice (in C57BL/6 background) was generated by 
crossing PPARδ f/f mice to albumin-Cre transgenic mice. Mice were fasted overnight for 
serum collection, tissue harvesting and glucose tolerance test (GTT). Insulin tolerance 
test (ITT) was performed after a 6 hour fast. A similar metabolic phenotype was 
observed in two additional cohorts (n=5), which were used for metabolic cage studies 
and to determine adenine nucleotide concentrations. The experiment was repeated in 3 
months old chow fed mice to evaluate gene expression at the fed state (n=4/group). 
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Statistics analyses were performed using Student’s t-Test (2-tailed), unless otherwise 
indicated. Values were presented as means±SEM. Significance was established at 
p<0.05. Animal studies were approved by the Harvard Medical Area Standing 
Committee on Animals. 
 
Metabolic studies 
 
Metabolic cage studies were conducted in a Comprehensive Lab Animal 
Monitoring System (Columbus Instruments, Columbus, OH). Mice were placed in 
metabolic cages for 2 days and data were collected at the beginning of the second dark 
(active) cycle for 24 hours. The respiratory exchange ratio was determined by the ratio 
of CO2 produced (VCO2) over O2 consumed (VO2). The values of RER during the dark 
(active) and light (rest) cycle were averaged (Figure 2.3). As mice were on high fat diet, 
RER was close to 0.7 throughout the day (RER=0.7 for fatty acid usage; RER=1 for 
glucose usage). For GTT 1.5 mg glucose/g body weight was injected into the 
peritoneum. Blood glucose was measured before and after injection at the indicated 
time points using the OneTouch glucose monitoring system (Lifescan, Milpitas, CA). ITT 
was conducted similarly (0.5 u insulin/kg body weight). To determine triglyceride 
production, mice were injected with Triton WR1339 (500 µg/g body weight) and blood 
was drawn via tail bleeding at different time points for triglyceride concentration 
measurement. Serum and hepatic triglyceride, non-esterified fatty acid, total cholesterol 
as well as serum ALT and AST were measured using commercial kits (Wako Chemicals 
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and ThermoDMA). Hepatic glycogen was determined as described [47]. Insulin and 
adiponectin were measured using ELISA kits (Linco, St. Charles, MO). Adenine 
nucleotides (ATP, ADP and AMP) were determined in perchloric acid extracts of freeze 
clamped tissues and normalized by protein concentration as described previously [48]. 
Hepatic fatty acid/triglyceride composition was determined by gas-liquid 
chromatography as described [40]. 
 
Histology, gene expression and signaling analysis 
 
Liver samples were either cryo-preserved for GFP detection or fixed in formalin 
for H&E or PAS staining. All of the histology work was performed in the Dana Farber 
Research Pathology Cores, which provided preliminary histological assessment by a 
pathologist. SYBR green-based real-time quantitative PCR (RT qPCR) reactions were 
conducted as described [28], using 36B4 levels as loading controls to obtain relative 
expression levels. For Western blot analyses, tissue or cell lysates were prepared in a 
buffer containing protease and phosphatase inhibitors. Antibodies against AMPK, Akt, 
Erk and JNK were purchased from Cell Signaling and PPARδ and actin antibodies were 
from Santa Cruz. For reporter assays, the 2kb and 0.3kb mouse GK (liver-specific) as 
well as the 3 kb mouse FAS promoter fragment were cloned in the pGL3-basic vector 
(Promega). Human ACC2 promoters I and II (all in pGL3-basic) were as described 
previously [28]. The resulting reporter was co-transfected with expression vectors for 
PPARδ/RXRα, SREBP-1c, PGC-1α and PGC-1β, all under the control of a CMV 
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promoter, together with a β-galactosidase internal control in HepG2 cells. Cells were 
harvested 40-48 hours after transfection and GW501516 (0.1 µM) was treated for 24 
hours. For endogenous gene regulation by PPARδ, primary hepatocytes were cultured 
in Williams’ E medium with 5% lipoprotein deficient, dialyzed FBS supplemented with 
100 nM insulin and treated with 0.1 µM GW501516 for 6 hours. 
 
In vitro functional assays 
 
Primary hepatocytes were isolated from 2-3-month old male C57BL/6 mice 
through portal vein perfusion with Blenzyme 3 (Roche, Indianapolis, IN) and cultured in 
Williams’ E medium with 5% regular FBS. Hepatocytes were infected with GFP or 
PPARδ virus for 24 hours. Cells were washed and incubated with DMEM (low glucose) 
for two hours. To measure glucose flux to glycogen synthesis, lipogenesis and 
oxidation, hepatocytes transduced with GFP or PPARδ virus were labeled with 1 µCi/ml 
D-[14C (U)]-glucose overnight with or without 100 nM insulin. Media was collected and 
cells lysed. For measuring glucose oxidation to CO2, the medium was transferred to a 
15 ml conical tube and 100 µl of 70% perchloric acid added. Filter paper pre-soaked in 1 
M NaOH was then placed on the top of the tube to capture CO2. Samples were 
incubated at 37°C overnight and the filters placed in scintillation vials to count 
radioactivity. Fatty acid oxidation was conducted by loading cells with 3H-palmitate 
(albumin bound). The rate of β-oxidation was determined by measuring 3H2O produced 
in the supernatant. For glycogen synthesis from labeled glucose, cellular glycogen was 
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isolated and the radioactivity determined. Glucose conversion to extractable lipids (fatty 
acid/triglyceride) was measured as described [28]. For glucose production, hepatocytes 
were incubated for 2 hours in glucose free DMEM, containing 1 mM pyruvate and 10 
mM lactate. Compound C (Calbiochem) and metformin (Sigma), an inhibitor and 
activator of AMPK, respectively, were added at the final concentration of 20 µM and 2 
mM. The glucose content in the supernatant was measured using a glucose oxidase kit 
(Trinity Biotech). All values were normalized by protein contents. Statistical analysis for 
glucose production was performed using one-way ANOVA. 
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Introduction 
 
Food intake increases the activity of hepatic biosynthetic pathways, notably de 
novo lipogenesis, which mediate the conversion of glucose to fats to be stored or 
oxidized. In mice, the hepatic lipogenic program is under direct control of the circadian 
rhythm peaking with nocturnal feeding [1, 2]. This temporal regulation is enforced by 
daytime repression of lipogenic genes by the nuclear receptor Rev-erbα via recruitment 
of an HDAC3-containing repressor complex [3]. The transcriptional activators of lipid 
synthesis in the dark cycle have not been well defined. While postprandial liver-derived 
lipids are important sources of energy production, disturbances in hepatic lipogenesis 
cause systemic metabolic phenotypes [4-8]. These observations indicate potential 
communications between liver and peripheral tissues in the control of energy substrate 
homeostasis. However, the underlying mechanisms remain unclear. 
 
Results 
Hepatic de novo lipogenesis modulates muscle fatty acid utilization 
 
 We have previously shown that the nuclear receptor PPARδ promotes hepatic 
fatty acid (FA) synthesis [9]. Despite the enhanced lipogenic activity, acute hepatic 
PPARδ activation through adenoviral PPARδ over-expression (adPPARδ) reduced 
circulating triglyceride (TG) and free fatty acid (FFA) levels (Figure 3.1A). Interestingly, 
FA uptake and β-oxidation were increased in isolated soleus muscle, compared to 
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control mice (adGFP) (Figure 3.1B). These findings raised the possibility of a PPARδ-
dependant signal coupling liver lipid metabolism to FA oxidation in muscle. To approach 
the mechanisms and identify the molecules involved, we performed untargeted liquid 
chromatography-mass spectrometry (LC-MS) based metabolomics profiling of hepatic 
lipids with a focus on metabolites of the PPARδ-regulated lipogenic pathway [10, 11]. 
Metabolite set enrichment analyses revealed the most significantly altered pathway in 
the adPPARδ/adGFP comparison was that of acetyl-CoA carboxylase (ACC), a rate 
limiting enzyme in de novo lipogenesis (Figure 3.1C). In direct contrast to the effects of 
hepatic PPARδ activation, acute liver-specific ACC1 knockdown (LACC1KD) reduced 
hepatic TG content and elevated serum TG and FFA levels (Figure 3.1D). Moreover, FA 
uptake was decreased in isolated soleus muscle from LACC1KD mice (Figure 3.1E). In 
vivo FA utilization was assessed using 3H-oleic acid tracers through portal vein injection. 
Taking into account the potential diurnal fluctuations in hepatic lipogenesis and fatty 
acid fluxes, we have performed this analysis at both the light and dark cycles.  The rate 
of 3H-oleic acid clearance in the circulation was decreased in LACC1KD mice in the 
dark/feeding cycle, when the lipogenic program is active (ZT18 or 12 am. Zeitgeber time 
ZT0: lights on at 6 am; ZT12: lights off at 6 pm) (Figure 3.1F). This defect was 
accompanied by reduced muscle FA uptake (Figure 3.1G). These results suggest that 
hepatic de novo lipogenesis is actively linked to muscle FA utilization, a process that 
can be experimentally separated from FA availability. 
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Figure 3.1. Hepatic de novo lipogenesis modulates muscle fatty acid utilization. A. 
Serum triglyceride (TG) and free fatty acid (FFA) level in GFP (adGFP) or PPARδ 
(adPPARδ) adenovirus injected mice fed a normal chow diet. Assays were carried out 4 
days after injection. B. Ex vivo fatty acid uptake (left) and oxidation (right) in isolated 
soleus muscle of adGFP and adPPARδ mice. C. Metabolite set enrichment analysis of 
lipids from adGFP and adPPARδ liver lysates. Metabolites were identified based on 
database search of matching mass-charge ratio and retention time. Identified 
metabolites and their relative quantity were used to calculate the enrichment and 
statistical significance. Top 30 perturbed enzyme or pathways were shown based on 
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(Figure 3.1. Continued) statistical significance. D. Hepatic TG (left) and serum TG 
(middle) and FFA (right) levels in adenovirus mediated liver specific scrambled 
(Scramble) or ACC1 (LACC1KD) knockdown mice. Representative immunoblots for 
ACC protein in Scramble and LACC1KD liver samples were shown. E. Ex vivo fatty acid 
uptake in isolated soleus muscle of Scramble and LACC1KD mice. F. Serum 3H 
radioactivity disappearance after portal vein infusion of 3H-oleic acid (left). The rate of 3H 
FA clearance is represented as the inverse of area under the curve (AUC) of 
disappearance (right). G. In vivo fatty acid uptake in soleus (left) and gastrocnemius 
(right) muscle of Scramble or LACC1KD mice. 3H-oleic acid complexed with 3.5% FA 
free BSA was infused through portal vein. Blood samples were collected at 1, 2, 5, 7, 
and 10 minutes. The assay was carried out at two time points: 12pm or zeitgeber time 6 
(ZT6), and 12am or ZT18 (ZT0: lights on at 6 am; ZT12: lights off at 6 pm). *p<0.05, 
two-tailed t-test. Data were presented as mean±SEM. 
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 Temporal regulation of hepatic lipogenic gene expression and serum lipidomes 
by PPARδ 
 
 To further explore the mechanism by which hepatic PPARδ controls crosstalk to 
the peripheral musculature, we examined the lipogenic pathway in liver-conditional 
PPARδ knockout (LPPARDKO, PPARδf/f x albumin-cre, C57BL/6) and control (wt, 
PPARδf/f) mice. Consistent with the PPARδ-ACC1 link in metabolomics analyses, 
induction of ACC1 in the dark cycle was abolished in the liver of LPPARDKO mice and 
the diurnal expression of ACC2, fatty acid synthase (FAS) and stearoyl-CoA desaturase 
1 (SCD1) was shifted (Figure 3.2A), indicating that PPARδ controls the temporal 
expression of hepatic lipogenic genes. In fact, PPARδ expression displayed diurnal 
oscillation that peaked in the dark cycle and coincided with the expression of Bmal1, a 
clock regulator with peak expression in the dark cycle, in the liver and in 
dexamethasone-synchronized primary hepatocytes (Figure 3.3A). The expression of 
diacylglycerol acyltransferase (DGAT1, triglyceride synthesis), choline kinase α (ChKα, 
phosphocholine synthesis) (Figure 3.2A) and core circadian clock genes (Bmal1, Per1, 
Cry1, and Rev-erbα) were unchanged in LPPARDKO mice, while the feeding activity, as 
determined in metabolic cage studies was unaltered (Figure 3.3B, C). Importantly, 
LPPARDKO resulted in reduced muscle FA uptake in the dark cycle in vivo, mirroring 
the results from LACC1KD mice (Figure 3.2B).  
 Products of de novo lipogenesis can exert diverse regulatory functions [12-14], in 
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addition to serving as energy substrates. Human and mouse metabolomic and lipidomic 
studies indicate that the serum lipid composition closely resembles that of the liver [15] . 
We also observed a 45% overlap between mouse liver and serum lipidomes (Figure 
3.4A), suggesting that changes in hepatic de novo lipogenesis may have significant 
effects on peripheral tissue metabolism through liver-derived circulating lipids. We 
therefore profiled lipidomes of serum samples from wt and LPPARDKO mice collected 
at 6 ZT points. A total of 735 unique ion features were detected in both positive and 
negative ionization modes. Hierarchical clustering of metabolites demonstrated a clear 
alteration in the pattern of serum lipids in LPPARDKO mice, compared to wt controls 
(Figure 3.2C). A dendrogram based on the clustering analysis revealed the main 
differences between these two genotypes occurred during the dark cycle (ZT16, 20 and 
24, or 10 pm, 2 am and 6am) (Figure 3.2D), when PPARδ-controlled lipogenesis is most 
active. Furthermore, principal component analysis (PCA) demonstrated similarities 
between LPPARDKO and LACC1KD serum in the dark cycle (Figure 3.2E), consistent 
with the reduced muscle FA utilization phenotype in both models. These findings 
support the notion that the PPARδ-ACC1 axis in the liver may modulate peripheral 
substrate utilization through serum lipid metabolites. 
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 Figure 3.2. Temporal regulation of hepatic lipogenic gene expression and serum 
lipidomes by PPARδ. A. Expression of PPARδ targets in the liver measured by RT-
qPCR. Liver samples from wild type (wt) and PPARδ liver specific knockout 
(LPPARDKO) mice were collected every 4 hours for a 24-hour cycle starting at ZT4. X 
axis: white bar represents light cycle time points (ZT4, 8, 12) and black bar represents 
dark cycle time points (ZT16, 20, 24). Statisitical significance was determined by two-
way ANOVA. #p<0.05 for significance between wt and LPPARDKO; +p<0.05 for 
significant differences of the circadian expression pattern. B. In vivo fatty acid uptake in 
soleus (left) and gastrocnemius (right) muscle of wt and LPPARDKO mice from two time 
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(Figure 3.2. Continued) points (ZT6 and ZT18). The assay was performed as in Figure 
3.1G.  C. Heat map of all identified positive and negative ionization mode features in LC-
MS based untargeted metabolomics. Features were arranged by unsupervised 
hierarchical clustering. D. Dendrogram based on hierarchical clustering of serum 
samples from wt and LPPARDKO mice. E. Principal component analysis of all identified 
positive mode features among wt, LPPARDKO, Scramble and LACC1KD serum. The 
score plot of the first three principal components, which represent 53.2% of total 
variation, was shown. *p<0.05, two-tailed t-test. Data were presented as mean±SEM.  
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 Figure 3.3. A. PPARδ and Bmal1 gene expression in wt and LPPARDKO liver (left), 
and dexamethasone synchronized wt primary hepatocytes (right). Circadian times refer 
to hours after dexamethasone treatment. PPARδ expression followed a similar pattern 
as that of Bmal1. B. Core circadian clock gene expression in the liver of wt and 
LPPARDKO mice. C. Food intake in wt and LPPARDKO mice measured by metabolic 
cages.  
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 Figure 3.4. A. Comparison of liver and serum lipidomes. Serum and liver features in 
both positive and negative ionization modes from wt mice were aligned with mass 
tolerance of m/z=0.01 and retention time tolerance of 60 seconds. Common features 
were filtered to remove isotopic peaks and peaks with ion intensities less than 5x104. B.  
Column purification of serum lipids scheme (See methods for detail). CHCl3: chloroform; 
IPA: isopropyl alcohol; MeOH: methanol; HOAc: acetic acid.  
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Identification of a serum phospholipid associated with hepatic PPARδ-ACC1 
activity 
 
 To test directly whether the PPARδ-mediated alterations in liver, and consequently, 
serum lipid composition are responsible for the muscle FA utilization effects, C2C12 
myotubes were incubated with serum or serum lipid extracts from LPPARDKO or control 
animals.  Treatment of myotubes with serum or lipid extracted from serum collected in 
the dark cycle from wt mice increased FA uptake, while serum or lipids derived from 
LPPARDKO animals had no such effect (Figure 3.5A,B). Delipidated serum also had no 
differential effects on FA uptake. Fractionation of serum lipids by column purification 
(Figure 3.5B) revealed that the activity stimulating FA uptake segregated with the 
phospholipid (PL) fraction (Figure 3.5B). To identify PLs that might mediate the 
functional interaction between hepatic lipid synthesis and muscle FA utilization, we 
compared liver or serum metabolomes from our three relevant models LPPARKO, 
LACC1KD, adPPARδ in positive ionization mode, which detects PLs as well as 
triacylglycerols (TG), diacyglycerols (DAG) and monoacylglyerols (MAG). A total of 158 
features were significantly altered in LPPARKO serum at ZT16/ZT20 compared to wt 
samples (p<0.05, corresponding to 19.6% FDR). 189 were significantly changed in 
LACC1KD serum compared to scramble controls at ZT16 (p<0.05, FDR=17%). Lastly, 
418 features were identified in liver lysates from adPPARδ mice compared to adGFP 
mice (P<0.05, FDR=11.3%). Cross-comparison of the metabolomes from these three 
models yielded 14 commonly changed features, whose putative identities were 
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assigned based on database search (Figure 3.5C,D). Among these, 4 molecules 
(PC[36:1], TG[56:7], TG[56:6], TG[58:6]) showed changes in the same direction in 
LPPARDKO (vs. wt) and ACC1KD (vs. control) but the opposite direction in PPARδ 
over-expression liver lysates (Figure 3.5D), corresponding to the observed muscle fatty 
acid utilization phenotypes. Based on the prior data that the differential activities toward 
FA utilization in C2C12 myotubes was in the serum PL fraction, we focused on the only 
one PL among the 4 molecules, m/z=788.6, putatively identified as PC(36:1). To 
determine the physiologic relevance of this PL, we examined the extracted ion 
chromatogram (EIC) of PC(36:1), m/z=788.6 over time and found this specific PL 
displayed diurnal rhythmicity peaking at night in serum from wt but not LPPARDKO mice 
(Figure 3.5E). PC(36:1) was also reduced in LACC1KD serum, while levels of this PL 
increased in lysates from hepatic PPARδ over-expression livers (Figure 3.5F). Co-
elution experiments with authentic PC(18:0/18:1) confirmed the identity of m/z=788.6 as 
PC(36:1) (Figure 3.5G, left). To define the exact fatty acyl-chain composition of this 
molecule, we performed tandem mass spectrometry scanning for lithiated adducts of 
PC(36:1) [16]. Only the PC(18:0/18:1) (1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine, 
SOPC) was above the detection limit, whereas PC(18:1/18:0) was virtually undetectable 
(Figure 3.5G, right). We then quantified SOPC in wt and LPPARDKO serum using 
tandem mass spectrometry with deuterated d83-PC(18:0/18:0) as the internal standard. 
The concentrations of SOPC in wt serum fluctuated ranging from ~70 μM during the day 
(ZT8) to ~130 μM at night (ZT20). While daytime SOPC levels remained similar 
between wt and LPPARDKO mice, the increase in serum SOPC in the dark cycle was 
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significantly diminished in PPARDKO mice (Figure 3.5H). Taken together, we have 
identified a serum lipid enriched in the dark/feeding cycle, whose levels were increased 
in the liver by PPARδ activation and decreased in serum by loss of function of hepatic 
PPARδ or the PPARδ target gene ACC1.  
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 Figure 3.5. Identification of a serum phospholipid associated with hepatic PPARδ-ACC1 
activity. A. In vitro fatty acid uptake in C2C12 myotubes treated with 2% serum pooled 
from light or dark cycle samples. Myotubes were pre-treated with serum for 48 hours 
and washed thoroughly with phosphate buffer saline (PBS) before subjecting to FA 
uptake assay (See methods summary for details). B. Fatty acid uptake in C2C12 
myotubes treated with 2% serum total lipids, delipidated serum or serum lipid fractions 
of diacylglycerol/monoacylglycerol (DAG/MAG), free fatty acids (FFA) and phospholipids 
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(Figure 3.5. Continued) (PL) (See Figure 3.4B for lipid fractionation scheme). C. Cross-
comparison of significantly changed lipids in three models: LPPARDKO vs wt serum, 
LACC1KD vs Scramble serum and adPPARδ vs adGFP liver lysates. D. Z-score plots 
of commonly changed features in three models using their respective controls as 
references. The putative identity was defined from database search. Both the H+ and 
NH4+ adduct of MAG(18:0) were identified. E. Representative Extracted ion 
chromatogram (EIC) of mz=788.6 in wt and LPPARDKO serum at three time points. F. 
Representative EIC of mz=788.6 in LACC1KD serum (left) and adPPARδ livers (right). 
G.  Co-elution of the PC (18:0/18:1) standard with mz=788.6. 100 pmol of PC(18:0/18:1) 
was injected as a separate sample (left). The acyl-chain composition of PC(36:1) was 
determined by tandem mass spectrometry running in multiple reaction monitoring 
(MRM) mode (right). Lithium chloride was added to mobile phases to facilitate adduct 
formation and fragmentation at sn-1 position of PC(36:1). Detailed MRM parameters 
were provided in Table. 3.2.  H. Quantification of PC(36:1) in wt and LPPARDKO mice 
serum using deuterated d83-PC(18:0/18:0) as the internal standard. *p<0.05, two-tailed 
t-test. Data were presented as mean±SEM.  
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PC(36:1) facilitates muscle fatty acid utilization 
 
To determine the biological activity of SOPC, we injected wt mice 
intraperitoneally with SOPC in the dark cycle. A single bolus injection significantly 
enriched SOPC (~1.4 fold) in serum after 4 hours (Figure 3.7A). SOPC injection 
coordinately altered lipid metabolism in a concentration-dependent manner, reducing 
elevated postprandial serum FFA and TG levels (Figure 3 . 6A),  w h i l e  increasing 
muscle FA uptake in vivo and ex vivo (Figure 3.6A, insert and Figure 3.6B), as 
compared to vehicle controls. Importantly, the reduced muscle FA uptake in 
LPPARDKO muscle was rescued by SOPC injection (Figure 3.6C). Induction of fatty 
acid uptake upon SOPC administration was associated with the induction of a panel of 
fatty acid utilization genes in the muscle, namely CD36, Cidea, FABP4, FATP4, DGAT1 
and PPARα (Figure 3.6D). Other FA transporters also exhibited a trend toward 
increased expression, including FATP1, FABP3 and FABP5, (Figure 3.7B-D). Similarly, 
the expression of these genes in the muscle was induced in adPPARδ mice and 
repressed in LPPARDKO and LACC1KD mice. Among those targets, CD36 is a well-
established regulator of muscle fatty acid uptake. Interestingly, CD36 expression at 
mRNA and protein levels also oscillated in wt muscle peaking in the dark cycle (Figure 
3.6E). This diurnal pattern was disrupted in LPPARDKO muscle. To assess the direct 
action of SOPC on muscle fatty acid utilization, we treated myotubes with 1 µM SOPC, 
its isomer PC(18:1/18:0) (OSPC), a non-specific phosphatidylcholine PC(17:0/17:0) or 
vehicle alone. Only SOPC was able to induce FA uptake in muscle cells. Furthermore, 
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the stimulatory effect of SOPC on fatty acid uptake was absent in CD36 knockdown 
myotubes, compared to controls (Figure 3.6F), supporting the notion that SOPC 
promotes muscle FA uptake and utilization. 
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 Figure 3.6. PC(36:1) facilitates muscle fatty acid utilization. A. Serum FFA (left) and TG 
(right) levels after i.p. injection of vehicle or PC(36:1) (SOPC) at the beginning of the 
dark cycle (ZT14). Feeding in the dark cycle led to a steady increase in postprandial 
serum levels of FFA and TG in vehicle treated mice. SOPC injection reduced 
postprandial serum FFA and TG in a dose dependent manner. Fold change was 
calculated using pre-injection FFA and TG values as references (ZT14). Insert: in vivo 
soleus muscle fatty acid uptake 4 hours after SOPC injection (5 mg/kg). B. Ex vivo FA 
uptake in isolated soleus muscle 4 hours after vehicle or 5mg/kg SOPC injection. C. In 
vivo FA uptake in soleus muscle 4 hours after injection of vehicle or 5mg/kg SOPC in wt 
or LPPARDKO mice. The injection was carried out at ZT14 and the assay was 
performed at ZT18. D. Transcriptional profiling of fatty acid utilization genes by high 
throughput RT-qPCR in muscle samples from SOPC vs Vehicle, adPPARδ vs adGFP, 
LACC1KD vs Scramble, and LPPARDKO vs wt. E. CD36 protein (upper) and gene 
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(Figure 3.6. Continued) (lower) expression in wt and LPPARDKO muscles. Statisitical 
significance was determined by two-way ANOVA. #p<0.05 for significance between wt 
and LPPARDKO. F. Fatty acid uptake in control or CD36 Stable knockdown C2C12 
myotubes pretreated with respective lipids overnight. FA uptake assay was performed 
as in Figure 3.5A,B. *p<0.05, two-tailed t-test. Data were presented as mean±SEM. 
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 Figure 3.7. A. Increased serum SOPC levels in wt mice 4 hours after a single dose 
injection of vehicle or 5mg/kg body weight SOPC. B-D. RT-qPCR transcriptional 
profiling of additional fatty acid uptake (FABP5, FABP3, FATP1) and phosphocholine 
transport (PCTP) genes in muscle from Vehicle and SOPC injected (B), adGFP and 
adPPARδ (C) and Scramble and LACC1KD mice (D). *p<0.05. 
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Discussion 
 
In summary, we have demonstrated that hepatic PPARδ signaling activates liver 
FA synthesis and peripheral FA utilization in multiple in vivo models. Using an 
integrated biochemical-cell biology based approach in these models, we identified 
SOPC as a hepatic PPARδ- and ACC1-dependent serum lipid that can modulate muscle 
FA utilization. Indeed, exogenous stimulation or administration of SOPC in vitro and in 
vivo replicates or rescues the patterns of hepatic lipogenesis on muscle FA oxidation. 
The peak PPARδ expression in the dark/feeding cycle does not completely overlap with 
that of lipogenic genes (Figure 3.2A and Figure 3.3A), suggesting that PPARδ activity 
may be controlled by ligands derived from de novo lipogenesis or intake of dietary 
nutrients. As expression of genes in the phospholipid synthesis pathway were not 
affected by loss of PPARδ function, the reduction in SOPC in LPPARDKO mice was 
likely due to decreased production of C18:0 and C18:1, products of de novo lipogenesis. 
The data presented here suggests that diurnal oscillations of the hepatic de novo 
lipogenesis pathway and lipid metabolite products align metabolic functions between 
liver and muscle. The integrated lipid synthesis and utilization is facilitated by temporal 
production of SOPC and muscle FA transporters. Such findings add to the evolving 
network of systemic signals from one organ to another that can coordinate metabolism 
in response to specific metabolic cues [12, 17, 18].  It will be of great interest to expand 
these networks to include the peripheral mechanism for how hepatic PPARδ-derived 
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SOPC controls levels of muscle CD36 and other FA transporters and the physiological 
relevance in human populations in future studies. 
 
Material and Methods 
Materials 
 
 PPARδ or GFP adenovirus was generated as described [9]. The shScrambled and 
shACC1 adenovirus were provided by Dr. Christopher Newgard [19]. Small hairpin RNA 
sequences against CD36 [20] or luciferase (control) was cloned in pSIREN-RetroQ 
vector.  
 
Animals  
 
 Mice used in the current study were all on the C57BL6/J background. Liver specific 
PPARδ knockout mice were generated by crossing albumin-cre transgenic mice to 
PPARδ f/f mice. Animals were housed in a barrier facility with 12-hour light and dark 
cycles. For circadian studies, animals were sacrificed every 4 hours starting at 10AM 
(ZT4) for 24 hours (n=4/genotype/time point) with free access to food and water. For 
dark cycle time points, animals were sacrificed under safety red light before proceeding 
to further dissection. Adenoviruses were injected through the tail vein (109 pfu/mouse). 
Subsequent metabolic characterizations were carried out 4 days post injection. 3 
cohorts were used for circadian studies (8-12 weeks old, 2 males and 1 female, showing 
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similar results). AdPPARδ/adGFP was repeated in 3 cohorts (8 weeks old male, n=4-6) 
and LACCKD was conducted in 2 cohorts (8 weeks old male, n=5). SOPC injection was 
performed in 2 cohorts (8-12 weeks old male, n=4-6). All animal studies were approved 
by the Harvard Medical Area Standing Committee on Animals. 
 
Metabolic studies 
 
 Metabolic cage studies were performed in a Comprehensive Lab Animal 
Monitoring System. Data were collected for 48 hours starting at the beginning of the 
dark cycle. TG and FFA were determined by colorimetric methods. Hepatic TG was 
determined from chloroform:methanol (2:1 v/v) extracts of vacuum dried liver samples.  
 
Primary hepatocytes and in vitro synchronization 
 
 Primary hepatocytes were isolated as described [21]. 100 nM of dexamethasone 
was applied for 1 hour to synchronize cells. After thorough wash, fresh culture media 
were added and cells were collected at the indicated time after dexamethasone 
removal. 
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Generation of stable C2C12 myoblast lines 
 
C2C12 myoblasts were infected with retroviral particles and selected against 
puromycin. Subsequent populations of puromycin resistant cells were collected as 
stock. Stable C2C12 CD36 or control knockdown myoblasts were able to differentiate 
into myotubes with no apparent defects. Differentiation of C2C12 myoblasts was 
performed in 2% horse serum, DMEM for 8 days. 
 
Gene expression and western blots 
 
Gene expression was determined by SYBR Green based real-time quantitative 
PCR (RT-qPCR) using 36B4 as an internal standard. A relative standard curve method 
was used to calculate the relative expression of genes. For high throughput RT-qPCR 
array, ddCt method was used to measure relative expression. The log2 fold change of 
the average expression of each probe was calculated. Hierarchical clustering and 
heatmap were generated by Cluster and Java Treeview. The primers used in this study 
were listed in table 3.1. Additional primer sequences were obtained from Primer Bank 
[22]. Protein levels of CD36 were determined by western blotting of muscle lysates 
using antibody against CD36 (Santa Cruz). For circadian samples, a pooled sample of 
wt and LPPARDKO (n=4) from each time point was used. For in vivo ACC1 knockdown, 
knockdown efficiency for each individual animal was determined by western blotting 
(n=5). Two representative animals from each group were shown (Figure 3.1D). 
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Table 3.1. List of primers used for RT-qPCR 
Genes Forward Sequence Reverse Sequence 
ACC1 CGCTCGTCAGGTTCTTATTG TTTCTGCAGGTTCTCAATGC 
FAS TCCTGGAACGAGAACACGATCT GAGACGTGTCACTCCTGGACTTG 
SCD1 CTTCTTCTCTCACGTGGGTTG CGGGCTTGTAGTACCTCCTC 
DGAT1 CATGCGTGATTATTGCATCC ACAGGTTGACATCCCGGTAG 
Rev-erbα TCTCTCCGTTGGCATGTCTAGA GCAAGCATCCGTTGCTTCTC 
CD36 TCATATTGTGCTTGCAAATCCAA TGTAGATCGGCTTTACCAAAGATG 
FABP4 TCACCGCAGACGACAGGAA CCACCAGCTTGTCACCATCTC 
FATP4 CATCAGCGTAAATGGGGATTTGG CTGTCGTCTGCGGTGATTTCATC 
Cidea TGCTCTTCTGTATCGCCCAGT GCCGTGTTAAGGAATCTGCTG 
PPARα TGTTTGTGGCTGCTATAATTTGC GCAACTTCTCAATGTAGCCTATGTTT 
FABP3 ACCTGGAAGCTAGTGGACAG TGATGGTAGTAGGCTTGGTCAT 
FATP1 CGCTTTCTGCGTATCGTCTG GATGCACGGGATCGTGTCT 
 
In vitro fatty acid uptake 
 
C2C12 myotubes were pre-treated with lipids complexed in 0.2% BSA (FA free) 
overnight. Cells were thoroughly washed with PBS before subjecting to a 5-minute FA 
loading with 1μCi/ml 3H-oleic acid in Krebs-Ringer Hepes (KRH) buffer, 1% FA free BSA 
and 100 μM oleic acid. Intracellular 3H radioactivity was determined and normalized to 
protein concentration. 
 
Ex vivo fatty acid oxidation 
 
  Mice were sacrificed and freshly isolated soleus muscles were incubated at 37 °C 
for 30 minutes with 2% FA free BSA containing KRH buffer supplemented with 0.2 mM 
palmitic acid, and 4 μCi/ml 3H-palmitic acid. Supernatants were collected and the 3H 
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radioactivity in the aqueous phase was quantified as described [23]. 
 
In vivo fatty acid uptake 
 
 We adapted an established protocol from Bartelt et al. [24]. Briefly, mice were 
anesthetized at different time of the day. 10 μCi of 3H-oleic acid complexed in 3.5% FA 
free BSA was infused through portal vein. Blood samples were collected at 1, 2, 5, 7 
and 10 minutes after infusion. At 10 minutes, soleus and gastrocnemius muscles were 
isolated. Serum radioactivity levels were determined at each time point. FA uptake was 
calculated as described [25]. 
 
Lipid extraction, fractionation and treatments 
 
 Serum lipids were diluted with phosphate buffer saline (PBS) and extracted by 
chloroform:methanol (2:1:1 v/v). The organic phase (lipids) was evaporated under a 
constant stream of nitrogen. Lipids were re-dissolved in chloroform. Column purification 
of serum lipids was carried out as described [26]. Briefly, Aminopropyl column (Sep-Pak 
Vac NH2 cartridge 3cc/500mg 55-105 μm, Waters) was equilibrated 3 times with 
acetone/water (7:1). Lipids in chloroform was dried under nitrogen and re-dissolved in 
hexane/methyl-butyl-tert-ether (MBTE)/acetic acid (100:3:0.3). Lipids were loaded on to 
the equilibrated column and were eluted sequentially with hexane, 
hexane/cholorform/ethyl aceate (100:5:5), chloroform/2-propanol (2:1) 
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(diacylglycerol/monoacylglycerol fraction), chloroform: methanol/acetic acid (100:2:2) 
(free fatty acid fraction), and methanol/chloroform/water (10:5:4) (phospholipids 
fraction). Each fraction was dried under nitrogen and re-dissolved in chloroform. For in 
vitro experiments, lipids were dissolved in 0.2% fatty acid (FA) free BSA in DMEM with 
2% double stripped FBS (charcoal stripped and lipoprotein deficient). The resulting 
solution was applied to cells overnight. Cells were washed extensively before subjecting 
to functional assays. For in vivo experiments, SOPC was re-suspended with sonication 
in 0.5% FA free BSA in PBS [12] to make a stock solution of 0.4 g/L. The solution was 
made fresh each time. Unless otherwise indicated, 5mg/Kg body weight SOPC was 
injected i.p.  
 
Liquid-Chromatography Mass-Spectrometry (LC-MS) 
  
 A 2:1:1 chloroform:methanol:PBS solution was prepared for lipid extraction to 
isolate organic soluble metabolites. Following brief vortexing, samples were centrifuged 
at 2500 x g at 4 °C for 10 minutes.  The organic layer (bottom) was transferred to a new 
vial and solvents were evaporated under a stream of nitrogen.  Samples were 
resuspended in chloroform (120 μl) and stored at -80 °C until LC/MS analysis (within 48 
hours of extraction).  For both positive and negative ionization mode LC-MS runs, 20 μl 
of extract was injected. LC-MS analysis was performed using an Agilent 6210 Accurate-
Mass time-of-flight LC-MS system as described [10, 11].  For LC analysis in negative 
mode, a Gemini (Phenomenex) C18 column (5 mm, 4.6 x 50 mm) was used together 
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with a pre-column (C18, 3.5 mm, 2 x 20 mm). Mobile phase A consisted of 95:5 
water:methanol and mobile phase B was composed of 60:35:5 
isopropanol:methanol:water. Both A and B were supplemented with 0.1% ammonium 
hydroxide solution (28% in water).  The flow rate for each run was 0.5 ml/min.  The 
gradient started at 0% B for 5 minutes and linearly increased to 100% B over 40 
minutes, was then maintained at 100% B for 8 minutes before re-equilibrating for 7 
minutes at 0% B.  For the LC analysis in positive mode, a Luna (Phenomenex) C5 
column (5 mm, 4.6 x 50 mm) was used together with a pre-column (C4, 3.5 mm, 2 x 20 
mm). Mobile phase A and B and the gradient were the same as for positive mode, but 
supplemented with 0.1% formic acid and 5 mM ammonium formate. MS analysis was 
performed with an electrospray source ionization (ESI) interface. The capillary voltage 
was set to 3.0 kV and the fragmentor voltage to 100 V.  The drying gas temperature was 
350 °C, the drying gas flow was 10 L/min, and the nebulizer pressure was 45 psi.  Data 
was collected using a mass range from 100-1500 Da. For wt and LPPARDKO serum 
samples, all samples of each genotype from different time points were detected in a 
single consecutive run. To validate the results, samples from ZT8, ZT16 and ZT24 were 
subject to a second run. For Scramble and LACC1KD serum or GFP and PPARδ liver, 
the entire sample set was run in a single session. 
 
Targeted analysis of phosphocholine species 
 
Side-chain composition of phosphocholine species. Phosphatidylcholine fatty acyl chain 
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composition was analyzed separately on an Agilent 6410 triple quadrupole-mass 
spectrometer (QQQ-MS) by direct injection of 1 μl of serum lipid extracts without 
chromatography [16]. The QQQ-MS was operated in multiple reaction monitoring mode 
(MRM), targeting lithium adduct precursors and product ions. The full list of MRM 
transitions and parameters is detailed in the table 3.2. Mobile phase was comprised of 
98:2 methanol:water with 1 mM LiCl to facilitate the formation of lithium adducts for 
analysis. Samples were run in positive ionization mode with fragmentor voltage of 150 
V, collision energy of 35 V and a dwell time of 25 ms. 
Quantification of phosphocholine species. 200 pmol of 1,2-distearoyl(d70)-sn-glycero-3-
phosphocholine-1,1,2,2-d4-N,N,N-trimethyl-d9 (D83 PC(18:0/18:0)) was spiked into 50 
μl of serum as the recovery standard. Serum was extracted as above. LC-MS/MS 
analysis was performed using an Agilent 6410 QQQ-MS in positive ionization mode 
equipped with an electrospray source ionization interface and an Agilent 1200 Binary 
Pump. For LC analysis a Gemini (Phenomenex) C18 column (50 mm x 2.0 mm, 3 μm 
particle size with 100 angstrom pore) was used with a 50 μm steel mesh filter.  Mobile 
phase A consisted of 95:5 water:methanol and mobile phase B consisted of 80:20 
isopropanol:methanol.  Both A and B were supplemented with 0.1% formic acid.  The 
flow rate was 0.3 ml/min.  The gradient started at 20% B and linearly increased to 100% 
B over 45 minutes, was maintained at 100% B for 10 minutes before equilibrating for 5 
minutes at 20% B. The QQQ-MS was operated in MRM mode and PCs were targeted 
using the m/z [M + H]+ to m/z 281.2 transition for all PCs.  Capillary voltage was set to 
3.0 kV, the fragmentor voltage to 200 V with a collision energy of 35 V.  The drying gas 
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temperature was 350 ºC, the drying gas flow was 10 L/min and the nebulizer pressure 
was 45 psi. The integrated peak area for each species was normalized to the peak area 
of the recovery standard.  
 
Table 3.2. List of multiple reaction monitoring (MRM) parameters for the identification of 
acyl-chain composition of PC(36:1).  
Phosphatidylcholine Precursor Ion [M+Li]+ Product Ion 
C18:1/C18:0 794.6 453.4 
C18:0/C18:1 794.6 451.4 
 
 
Data analysis (Figure 3.9) 
 
Data preprocessing. Raw data files were converted to mzXML files and subsequently 
aligned by XCMS [27]. The resulting aligned features derived from wt, LPPARDKO, 
Scramble and LACC1KD serum were compared to identify common features using 
metaXCMS [28] with a mass tolerance of 0.01 and retention time tolerance of 60 
seconds. Identical procedures were carried out to generate common features from 
adPPARδ and adGFP liver lysates. Subsequently, these features from serum and liver 
lysates samples were processed by an automated workflow [29] to identify isotopic 
peaks and assign putative identity with 3ppm mass tolerance. All isotopic peaks were 
removed and the remaining data were cutoff for features with median intensity less than 
5x104. The reproducibility of the untargeted metabolomics platform was evaluated from 
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two independent runs of 6 samples. The Spearman’s rank correlation coefficient was 
calculated and the duplicate pair with lowest correlation coefficient was plotted (Figure 
3.8A).  
Data normalization. We adapted methods from Sreekumar et al [30]. Briefly, each 
sample was centered by median and scaled by its inter-quartile range (IQR). The 
normalized distributions of samples were plotted in Figure 3.8B as Box-and-Whisker 
plot.  
Hierarchical clustering. Both positive and negative ionization mode features from wt and 
LPPARDKO serum around the clock were mean centered and scaled by standard 
deviation on a per feature basis (auto-scaling). To simplify the visualization, only the 
mean value of each feature from every time point was used for the construction of heat 
map. The resulting data sets of each genotype were clustered using Euclidean distance 
as the similarity metric in Cluster 3.0. Heat maps were generated by Java Treeview. 
Heat map of LPPARDKO serum was aligned to wt for comparison. Dendrogram of 
samples was plotted based on Spearman correlation with Ward linkage.  
Principal component analysis. Auto-scaling was applied on a per metabolite basis to 
each biological group (wt vs LPPARDKO and Scramble vs LACC1KD). Principal 
component analysis was performed in Metaboanalyst [31]. The 3D view of the first 3 
principal components was plotted.  
Identification of significant features. The empirical p-value for each pair of comparison 
was calculated by randomly permuting sample labels for 1000 times to obtain the null 
distribution. The analysis was carried out in Multiple Experiment Viewer [32]. False 
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discovery rate was determined by Benjamini-Hochberg method. A feature is considered 
significant for downstream cross-comparison with unadjusted p<0.05. Significantly 
changed features in wt and LPPARDKO mice serum at night (n=6, pooled sample set 
from ZT16 and ZT20), Scramble and LACC1KD mice serum (n=5), and adGFP and 
adPPARδ liver lysates (n=4) were compared and visualized in Venn diagram.   
Metabolites Set Enrichment Analysis (MESA). Significantly altered features in 
adPPARδ/adGFP liver lysates comparisons were assigned putative identities based on 
database search. Their identities were further validated from an internal reference 
database. Validated lipid species were matched to human metabolites database 
(HMDB). The mappable species were assigned a HMDB ID for subsequent MESA 
analysis implemented in the Metaboanalyst [31]. 
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 Figure 3.8. A. The reproducibility of the untargeted metabolomics platform was 
validated from two separate runs of 6 serum samples. The Spearman’s rank 
correlations are between 0.9 and 0.94. The duplicate pair with the lowest correlation 
(Spearman’s r=0.90) is shown. B. Raw intensity of samples was subject to 
normalization with median centering and inter-quartile range (IQR) scaling. The resulting 
data show equal distribution among different groups of samples. White bar represents 
samples obtained in the light cycle and black bar for those in the dark cycle.  
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Figure 3.9 
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(Figure 3.9. Continued) Flow chart of metabolomics data analysis (See methods for 
detailed description). 
 
Statistical analysis 
 
 Unless otherwise noted, statistical significance was calculated by unpaired, two-
tailed student’s t test. In time series data, two-way ANOVA was performed. Significance 
was set at p<0.05.  
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Chapter 4: 
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Summary and Significance of Thesis Work 
 
 The main focus of this thesis work is to understand the role of hepatic de novo 
lipogenesis in controlling systemic metabolic homeostasis. In chapter 2, we identified 
the nuclear receptor PPARδ as a transcription factor regulating de novo lipogenesis in 
the liver. Activation of hepatic PPARδ induces key genes involved in de novo 
lipogenesis such as ACC1/2 and SCD1. We characterized the molecular mechanism for 
PPARδ mediated activation on these genes using promoter reporter assays. We 
demonstrated direct transcriptional activation by PPARδ on these genes. In addition, we 
demonstrated that the activity of PPARδ in the liver is controlled via two mechanisms: 
(1) the initial activity of PPARδ generates endogenous ligands of PPARδ, thereby 
creating a feed forward mechanism of activation; (2) the nuclear receptor co-activator 
PGC-1β, previously implicated in mediating the lipogenic effects of fructose [1] and 
saturated fatty acids [2], was shown to co-activate PPARδ. We further addressed the 
effects of acute PPARδ activation on global glucose homeostasis and insulin sensitivity 
under pathophysiological conditions. High fat diet (HFD) fed mice had significantly 
improved glucose tolerance, reduced hepatic glucose production and improved insulin 
sensitivity upon PPARδ overexpression in the liver. These metabolic improvements 
were associated with reduced hepatic inflammation and enhanced AMPK activation.  
 During the course of the study, we unexpectedly observed significantly reduced 
serum lipid concentrations, despite increased hepatic lipid synthesis and normal 
triglyceride output in PPARδ overexpression (adPPARδ) mice. This prompted us to 
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hypothesize that extra-hepatic tissues had enhanced lipid clearance. This was indeed 
the case. We demonstrated a link between hepatic de novo lipogenesis and muscle 
fatty acid utilization in vivo. Treatment of fully differentiated C2C12 myotubes with serum 
obtained from wild type (WT) or liver specific PPARδ knockout (LPPARDKO) mice 
recapitulated the effects seen in vivo, suggesting that serum factor(s) might be 
responsible for this inter-organ communication. Using the untargeted metabolomics 
approach, we compared the serum lipid profile from multiple genetic models that display 
differential muscle fatty acid utilization. This comparison yielded a PC species, 
PC(18:0/18:1) or SOPC, as the likely candidate.  Administration of SOPC promoted fatty 
acid utilization in the muscle, thereby confirming the role of SOPC as a lipid mediator 
linking lipogenic activity in the liver with fatty acid utilization in the muscle.  
 Although these findings provide a glance into inter-organ communication through 
biosynthetic pathways, several questions remain to be answered.  The impact of 
reduced fatty acid uptake in the muscle under normal physiological and 
pathophysiological conditions warrants further study. With regard to the circadian 
regulation of PPARδ activity and SOPC levels, whether it is driven by the acute 
response to feeding, systemic signal from the central clock or the endogenous clock in 
the liver is not fully understood. The specificity, potency and mechanism of action of 
SOPC on muscle fatty acid uptake are also not clear. These aspects will be discussed 
below. 
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PPARδ Signaling and Metabolic Flexibility 
I. Hepatic PPARδ Activation and Metabolic Flexibility  
 
Although the improved glucose homeostasis in PPARδ overexpression animals 
under HFD can be attributable to the removal or sequestration of deleterious 
intermediate metabolites that impair insulin actions, in chapter 2, we demonstrated a 
direct transcriptional regulation of PPARδ on hepatic glucokinase, a rate-limiting 
enzyme in glycolysis. Furthermore, acute activation of PPARδ elevates AMPK activity in 
primary hepatocytes, leading to decreased glucose production. These data suggested a 
direct regulatory role of PPARδ in both glucose and lipid metabolism. Therefore, the 
unique action of hepatic PPARδ suggests a potential therapeutic strategy to combat the 
metabolic inflexibility associated with the insulin resistantance. By channeling glucose 
into lipids for storage and reducing glucose output, acute activation of hepatic PPARδ 
may be an alternative route to restore metabolic flexibility. This idea is akin to the 
beneficial effects seen in several animal models with enhanced adipose tissue 
lipogenesis [3-5]. However, liver is not the major site for lipid storage. The accumulation 
of lipid droplets may eventually exceed the capacity of hepatocytes, causing cellular 
dysfunction and eventually insulin resistance, as seen in liver specific SREBP1c 
transgenic mice. Therefore, the extent of benefits upon hepatic PPARδ activation over 
long term remains to be evaluated.  
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II. The Role of PPARδ Signaling in Normal Physiology 
 
 In chapter 3, we established a liver-muscle crosstalk coupling fatty acid synthesis 
to fatty acid utilization. How this crosstalk might impact overall metabolic homeostasis 
has not been examined. The ability to utilize fatty acids is central to maintaining 
metabolic flexibility. We hypothesize that a lack of fatty acid utilization promotes glucose 
utilization to compensate for the energy needs in the muscle. To test this hypothesis, we 
measured blood glucose levels in both LPPARDKO and ACC1 knockdown (LACC1KD) 
mice. These two models had reduced fatty acid uptake in the muscle, but lowered blood 
glucose level specifically in the dark cycle, suggesting an increase in glucose utilization 
(Figure 4.1A). Consistent with these observations, adPPARδ mice and mice injected 
with SOPC had reduced glucose utilization in the muscle (Figure 4.1B). In ad libitum 
conditions, these changes may have little impact to the overall metabolic fitness. 
However, we reason that in the wild, where food access is periodical, this mechanism 
may play a key role in metabolic adaptation. To test this idea, we performed a 
preliminary experiment using daily restricted feeding as a model to mimic wild condition. 
We sampled blood glucose and TG levels every 8 hours for 3 consecutive days starting 
at the first day of restricted feeding in WT and LPPARDKO mice. Indeed, after the initial 
acute response to fasting and feeding, WT mice quickly adapted to this new feeding 
scheme and their blood glucose levels were stabilized. In contrast, LPPARDKO 
continued to have a large fluctuation of blood glucose levels following fasting and 
feeding cycle, indicating an impaired mechanism to switch from glucose to fatty acid 
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utilization during the fasting state (Figure 4.1C). To further support this notion, we 
looked at their serum TG levels over the course of the experiment. LPPARDKO mice 
had higher serum TG levels compared to WT counterparts, suggesting the lack of fatty 
acids utilization in these animals (Figure 4.1C). As such, the fluctuation of blood glucose 
may hinder the metabolic adaptation of LPPARDKO mice in the wild.  
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Figure 4.1. The role of PPARδ signaling in normal physiology. A. Blood glucose levels 
in LPPARDKO or LACC1KD mice and their controls around the clock. For WT and 
LPPARDKO mice, blood glucose was measured every 4 hours starting at ZT4 (left). For 
LACC1KD and Scramble mice, blood glucose was measured every 6 hours starting at 
ZT6. (ZT, Zeitgeber time. ZT0: 6AM and ZT12: 6PM). White bar: light cycle, black bar: 
dark cycle.  B. Ex vivo muscle glucose uptake. Soleus muscle was isolated from mice 
with respective treatments. 3H labeled 2-deoxy-glucose was used to measure glucose 
uptake. Normalized radioactivity accumulation in the muscle was determined as the 
glucose uptake capacity. C. WT and LPPARDKO mice were fasted from ZT12 to ZT4 
the ensuing day for 3 consecutive days. Red bar: time when food was presented. Blood 
glucose (left) and serum TG levels (right) were measured every 8 hours for the 
experimental period. Blood glucose levels were expressed as the fold change of the 
initial concentration. *p<0.05, two-tailed student’s t-test. Value was expressed as 
mean±SEM.  
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III. The Role of PPARδ Signaling in Pathophysiology 
 
 While de novo lipogenesis is important in normal physiology, current western diet 
has pushed the metabolic balance toward excessive hepatic lipogenesis. Therefore, 
limiting fatty acid uptake in the muscle may relieve the metabolic stress caused by 
lipotoxicity. HFD induced hepatic lipogenesis and increased serum SOPC 
concentrations compared to chow fed controls (Figure 4.2A). Elimination of hepatic 
PPARδ reduced de novo lipogenesis in vivo, suppressed serum PC(36:1) (SOPC) 
concentrations and lowered muscle fatty acid uptake (Figure 4.2B). Consistent with 
these data, a euglycemic-hyperinsulinemic clamp study indicated improved glucose 
utilization in LPPARDKO mice as measured by glucose infusion rate. This improvement 
was contributed by both the reduced hepatic glucose production under clamp and 
increased muscle glucose uptake (Figure 4.2C).  
 Does SOPC cause glucose intolerance and insulin resistance? In the case of 
prolonged activation of this pathway, such as under HFD, the muscle is unable to switch 
from fatty acid utilization to glucose oxidation and is overloaded with deleterious lipid 
intermediates, thereby causing insulin resistance. However, although not directly 
addressed in this thesis work, acute increase in serum SOPC levels may provide 
beneficial effects by reducing the circulating lipid levels and alleviating lipotoxicity. The 
seemingly contradicting role of SOPC mediated muscle fatty acid utilization resembles 
the opposing metabolic effects of prolonged versus acute activation of hepatic de novo 
lipogenesis discussed in the previous section. Thus it is necessary to emphasize that 
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the metabolic flexibility is maintained through balanced actions of multiple physiological 
processes. The eventual outcome of the PPARδ-SOPC mediated fatty acid utilization 
program is dependent upon the duration and perhaps the timing of its activation. Future 
experiments will be needed to elucidate whether SOPC alone is sufficient to cause 
insulin resistance upon prolonged administration, and to determine the timing of its 
induction with respect to other HFD induced signaling pathways.   
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Figure 4.2. The role of PPARδ signaling in pathophysiology. A. Serum concentrations 
of PC(36:1) or SOPC determined by targeted metabolomics. WT mice were fed on HFD 
or chow for 4 months before being sacrificed at two time points of the day (ZT8, 2PM 
and ZT20, 2AM). B. WT and LPPARDKO mice were put on HFD for 2 months. Hepatic 
de novo lipogenesis was measured by stable tracer D2O (left), serum PC(36:1) or SOPC 
concentrations were determined by targeted metabolomics (middle) and ex vivo fatty 
acid uptake in the soleus muscle was determined by 3H labeled oleic acid (right) (See 
chapter 3 methods for details). C. WT and LPPARDKO mice were subject to a 
euglycemic-hyperinsulinemic clamp after 2 months on HFD. The exogenous glucose 
infusion rate (GIR), hepatic glucose production (HGP) under basal or clamped 
conditions, and tissue specific glucose uptake at the end of the clamp were determined. 
*p<0.05, two-tailed student’s t-test. Value was expressed as mean±SEM. 
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PPARδ, a New Player in the Circadian Regulatory Network 
 
 In chapter 3, we attempted to evaluate the possibility that hepatic PPARδ is 
directly under the control of endogenous clock by using synchronized primary 
hepatocytes. We observed persistent PPARδ expression cycle similar to other core 
clock genes in the primary hepatocytes without external stimuli. Although the expression 
of PPARδ can be regulated by the liver endogenous clock, the expression of lipogenic 
targets of PPARδ, SOPC levels and muscle CD36 expressions cannot be addressed 
using this minimal system. The benchmark assay to determine whether a biological 
process is controlled by endogenous clock in the liver is to perform reverse feeding. 
Peripheral clock, especially in the liver is subject to the regulation from food derived 
cues. Restricted feeding during the day sets the peripheral clock independent of the 
central clock. After 7 days of restricted feeding with WT and LPPARDKO mice, we 
observed a complete switch of the liver clock with the peak expression of Rev-erbα, the 
daytime marker, shifting to the dark cycle (Figure 4.3A). The hepatic expression of 
PPARδ target ACC1 was opposite to what was seen under ad libitum feeding conditions 
in the WT mice, whereas in LPPARDKO mice, the expression of ACC1 did not exhibit 
strong reversed rhythm and the overall expression level was lower (Figure 4.3A). 
Consistent with these findings, CD36 expression in the LPPARDKO muscle did not 
have reversed expression profile as seen in WT muscles (Figure 4.3A). Taken together, 
these experiments suggest that the PPARδ-SOPC-CD36 axis is directly under the 
control of endogenous liver clock instead of signals from the central clock, as this would 
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not result in reversed expression profile, given the identical lighting condition.  
 Although these experiments would differentiate light versus food derived cues, 
they are not sufficient to distinguish whether the PPARδ-SOPC-CD36 program is 
associated with mere acute response to feeding, as opposed to the food entrainable 
clock regulated program. In fact, we provided evidence that fatty acids or PGC1β 
binding are capable of activating PPARδ associated lipogenic program in chapter 2. 
Thus the relative importance of clock regulated versus acute substrate or co-factor 
binding driven PPARδ activity needs to be clarified.  
 The distinction between these two is minor: the food entrainable clock still 
requires food cues to exert its downstream physiological output. However, the idea of a 
clock system is to proactively regulate biological processes. One would predict that 
certain biological processes in response to food would be maximized or minimized as 
the endogenous clock is set to a new time by restricted feeding. In other words, if a 
process is controlled by local clock, the response of this process to feeding will be 
different as restricted feeding continues, whereas a pure acute response will have the 
same degree of response each day. By examining the expression profile of hepatic 
PPARδ and muscle CD36 as well as serum concentrations of SOPC over the course of 
a consecutive reverse feeding experiment as described earlier, the change of these 
readouts therefore is able to discern whether the hepatic PPARδ controlled program is 
regulated by the food entrainable clock.  
We intend to determine the core clock protein that is directly responsible for the 
circadian expression of PPARδ. Given that large scale ChIP-seq experiments have 
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been performed on each core clock genes in the liver, a bioinformatics search for core 
clock genes bound to the PPARδ upstream regulatory region is possible [6-8]. Publicly 
available data show several binding peaks of the core clock gene Rev-erbα and β on 
PPARδ 5’-UTR region, suggesting a regulatory role (Figure 4.3B). Rev-erbα and β have 
already been identified as the master repressor for hepatic de novo lipogenic program 
[7, 9]. Yet combined knockout or pharmacological inhibition of these genes in the liver 
does not lead to constitutively elevated lipogenic gene expression [7, 10]. Rather, those 
mouse livers show shifted expression pattern, suggesting the involvement of additional 
transcription factors, such as PPARδ. We preliminarily explored this possibility.  
Overexpression of Rev-erbα in primary hepatocytes led to reduced expression of 
PPARδ (Figure 4.3C). Further studies are warranted to examine whether Rev-erbα and 
β are able to control PPARδ and its associated program in vivo. 
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Figure 4.3. PPARδ, a new player in the circadian regulatory network. A. WT and 
LPPARDKO mice were subject to 7 days of restricted feeding with the feeding time 
restricted between ZT0 and ZT8 (red bar). Mice were sacrificed every 4 hours starting at 
ZT0 for 24 hours. Liver (Rev-erbα and ACC1) and muscle (CD36) gene expression was 
measured by real-time PCR. B. Chip-Seq signals of Rev-Erbα/β around PPARδ 
genomic location in the liver. The data was obtained from Cho et al. [7]. C. Primary 
hepatocytes were transduced with either GFP or Rev-Erbα adenovirus for 48 hours. 
PPARδ gene expression was determined by real-time PCR. *p<0.05, two-tailed 
student’s t-test. Circadian gene expression data were tested by Two-way ANOVA. 
#p<0.05 for genotype significance and +p<0.05 for genotype-time interaction 
significance. Value was expressed as mean±SEM. 
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The Biology of SOPC 
I. SOPC Synthesis, Output and Delivery 
  
 To fully understand the physiological relevance of the liver and muscle crosstalk, 
it will be critical to determine how SOPC is produced, transported out from the liver and 
delivered to the muscle. We have so far linked the changes in hepatic de novo 
lipogenesis to serum SOPC levels. As discussed previously, Hepatic de novo 
lipogenesis provides fatty acyl-CoAs for the synthesis of phospholipids. There is very 
little information regarding how specific side chain composition is determined. PCs can 
be synthesized de novo through the Kennedy pathway [11]. In this pathway, the final 
enzyme catalyzing the addition of choline head group to DAG, CEPT1 has limited 
substrates specificity. It was shown that DAG(16:1/16:1), DAG(18:1/18:1) and 
DAG(16:0/18:1) are the major substrates [12]. The diversity of PC species is mainly 
generated from the remodeling process. Almost 50% of all PCs are derived from this 
pathway, termed Lands cycle [13, 14]. In this remodeling process, the sn-2 position is 
removed by phospholipases and a new acyl chain is added by lysophosphocholine 
acyltransferases (LPCATs). In the liver, the newly discovered LPCAT3 is perhaps 
responsible for the majority of the LPCATs activity in the liver [15]. It prefers unsaturated 
fatty acyl-CoAs with high activity toward arachidonic acid, linoleic acid and oleic acid as 
the substrates. Its expression is regulated by the PPARα ligands, suggesting a role of 
PPAR family nuclear receptors in the control of phospholipid remodeling. In chapter 2, 
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we showed significantly increased oleic acid and decreased palmitic acid levels in the 
liver of adPPARδ mice with no difference in linoleic acid and slightly reduced stearic 
acid levels. This lipid profile therefore may facilitate the synthesis of PC species 
containing stearic acid at the sn-1 and oleic acid at the sn-2 position. In a recent human 
genome-wide association study (GWAS), a single nucleotide polymorphism (SNP) 
within the coding region of the phospholipase PLRP2 that causes a non-synonymous 
mutation is associated with the percentage of serum PC(36:1) levels [16]. Given the 
minimal quantity of PC(18:1/18:0), it is likely that this mutation is associated with the 
serum level of PC(18:0/18:1) (SOPC). Therefore, it may provide the molecular 
mechanism that accounts for the SOPC production. 
 PCs are highly water insoluble and therefore they seldom spontaneously 
dissociate from the membrane structures [17]. Lipoproteins and cellular membranes are 
the main site of PC localization. Approximately 25% of the total ER membrane PCs is 
SOPC in the bovine liver [18]. In the postprandial state, hepatic de novo lipogenic 
activity is coupled with lipoprotein production and output through the ER-Golgi route 
[19]. Therefore it is likely that SOPC is attached to VLDL particles to be exported 
together with TG. This notion is tempting as it couples signaling molecules with energy 
substrates. However, future experiments are needed to profile the PC composition from 
all lipoprotein fractions in WT and LPPARDKO mice serum to test this hypothesis.  
 Once delivered into the circulation, SOPC, a charged lipid needs to cross the 
plasma membrane and exert its action in the muscle. How SOPC is recognized on the 
cell surface and enriched inside of the cell remain a question. Although we hypothesize 
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that SOPC is co-transported with lipoproteins, it does not appear that the action of 
SOPC is dependent on lipoproteins. In C2C12 cells, treatment of SOPC coupled with 
lipoprotein deficient FBS is sufficient to elevate fatty acid uptake. Therefore, the route of 
transport may be independent of lipoprotein particles. However, this does not rule out 
the ability of lipoprotein particles to facilitate its action. Three classes of proteins are 
known to transfer PCs intracellularly: (1) Phosphatidylcholine transfer protein (PCTP); 
(2) Phosphatidylinositol transfer protein (PITP); (3) Sterol carrier protein 2 (SCP2). 
PCTP has been demonstrated to be unable to bind to SOPC, while the PC substrate 
preference of PITP and SCP2 has not been extensively studied [20]. To this end, we 
have not been able to identify a potential mechanism through which SOPC is taken up 
and transported. To address this issue, new tools and techniques are likely required. 
We plan to collaborate with chemists to synthesize chemical probes including ether 
linked, isotope tagged, fluorophore tagged, and biotin tagged SOPC. These tools will 
facilitate the identification of its metabolic fate, cellular location and protein partners.  
 
II. SOPC as a Signaling Molecule? 
 
 Although our initial cross-comparison yielded SOPC as the only likely candidate, 
later targeted metabolomics profiling focusing on PC species has identified additional 
species that are down-regulated in LPPARDKO mice serum. This raised the concern on 
the specificity of SOPC action in the muscle. We set out to address these issues by 
choosing several related phospholipid species and testing their activities on muscle fatty 
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acid uptake in vitro and in vivo. We chose PC(18:1/18:0), PC(16:0/18:1), PC(18:1/18:1), 
PE(18:0/18:1), and PA(18:0/18:1) as control lipids. Some of these lipids have reduced 
levels in LPPARDKO serum. We reason that these lipids would be able to address 
whether the activity is derived from the sn-2 fatty acids, DAG, or head group. In vitro 
fatty acid uptake assay in C2C12 myotubes using these lipids demonstrated no 
significant stimulatory activity on fatty acid uptake (Figure 4.4A). For further validation, 
we injected SOPC, PC(16:0/18:1) or PC(18:1/18:1) into FVB/NJ mice and showed 
significant reduction in serum TG concentration only in SOPC treated group (Figure 
4.4B).   
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Figure 4.4. The specificity of SOPC. A. In vitro fatty acid uptake in C2C12 myotubes 
treated with PCs. 50 μM of the indicated PC species were applied to fully differentiated 
C2C12 myotubes overnight. Fatty acid uptake capacity was determined by 3H labeled 
oleic acid (See chapter 3 methods for details). B. Changes in serum TG contents after 
PCs injection. FVB/NJ mice were injected with indicated PCs via tail vein. Baseline and 
4 hours post-injection serum TG levels were determined. Food was removed during the 
experiment. SOPC was highlighted in red. Data were expressed as fold change of the 
baseline values. *p<0.05, two-tailed student’s t-test. Value was expressed as 
mean±SEM. 
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 While these experiments confirmed that SOPC has specific activity on muscle 
fatty acid uptake, it is possible that additional tissues are targets of SOPC and the 
specific activity in those tissues contribute to the overall reduction in serum TG. Adipose 
tissue and liver are the additional sites of consideration.  
 Our in vivo radiolabelled tracer experiments showed no difference in fatty acid 
uptake capability of the adipose tissue between WT and LPPARDKO mice or between 
vehicle and SOPC injected mice (data not shown). However, we have not examined in 
detail the molecular events in LPPARDKO or SOPC treated adipose tissue. Preliminary 
radiolabelled tracer study of WT mice in vivo showed diurnal difference in fatty acid 
uptake between adipose tissue and muscle (data not shown). The adipose tissue 
uptake peaks at early dark cycle, whereas the muscle uptake peaks late in the dark 
cycle. Serum SOPC concentration peaks late in the dark cycle, suggesting its role in 
mediating muscle fatty acid uptake. However, understanding the molecular targets of 
SOPC will also be helpful to delineate its tissue specificity, as the target protein may 
have limited expression profile among tissues.  
 Phospholipids are important constituents of VLDL particles [19]. Disrupted VLDL 
secretion can contribute to overall reduced serum TG levels. Adenovirus mediated 
overexpression of PPARδ in the liver did not alter TG production. Moreover, 
LPPARDKO mice did not have more TG accumulation in their livers, suggesting the lipid 
lowering effects of SOPC are unlikely contributed by impaired TG production (data not 
shown). Nevertheless, we have not directly addressed the effects of SOPC on liver 
metabolism. Future work using primary hepatocytes will be instrumental to examine the 
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role of SOPC on liver metabolism, if any.  
 A typical hormone has a large dynamic range, producing several fold higher 
concentration when induced, such as insulin and leptin [21]. However, serum SOPC 
concentrations increase only by two fold from day to night. Such a modest change 
challenges the idea that SOPC is a hormonal signal. Since PCs are likely partitioned 
into lipoprotein fractions, the biological activity may only be accessible in certain 
fractions. Lipidomics analysis of fasted human lipoprotein composition revealed that, of 
the approximately 2 mM of PCs, 62% are located in HDL, 30% in LDL and 8% in VLDL. 
In the same study, PC(36:1) was measured to account for about 2.5% of total PCs 
within each lipoprotein classes [22]. Therefore, the quantity of PC(36:1) is calculated to 
be 4 μM in VLDL, 14.8μM in LDL and 30.8 μM in HDL. If in the postprandial state, as 
discussed in the last section, SOPC is mainly enriched in the VLDL fraction due to its 
ER origin, a modest 20 μM increase would lead to a 1.4 fold increase in total SOPC, but 
a dramatic 5 fold increase in the VLDL fraction. Such a dynamic range would fit with its 
role as a regulatory molecule. Of course, this hypothesis needs to be rigorously tested 
using the targeted metabolomics profiling of ER and lipoprotein PCs with our genetic 
models.   
 We are also keenly aware that most of the changes elicited by SOPC in vivo are 
within two fold. As discussed in chapter 1, lipid metabolism and metabolism in general 
are tightly regulated by multiple pathways to achieve metabolic homeostasis. In fact, 
many physiological metabolic changes are of small magnitude. For example, many 
circulating metabolites have been found to fluctuate within two fold diurnally [21]. 
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Genome-wide expression profiling studies also demonstrated that alteration in metabolic 
gene expression between normal and metabolic disease states is less than 2 fold [23-
26]. It is because of this tight control, a 1.5 fold change in lipid concentration can be 
consequential. The impact of reduced fatty acid uptake under normal physiology and 
pathophysiological conditions has been discussed in earlier sections.  
 
III. Molecular Mechanism of Action 
 
 The molecular nature of SOPC’s action in the muscle remains a critical question 
to be addressed. A common consequence of lipid loading containing saturated fatty 
acids is the development of cellular insulin resistance, which exacerbates fatty acid 
uptake in the muscle. To determine whether the mechanism of SOPC’s action is due to 
cellular insulin resistance, we pretreated C2C12 myotubes with SOPC or vehicle and 
stimulated with insulin. The results did not suggest an impairment of insulin signaling 
judged by equal levels of Akt phosphorylation in both groups (Figure 4.5A). 
Furthermore, under chow diet condition, LPPARDKO mice did not show enhanced 
insulin sensitivity measured by glucose and insulin tolerance test compared to their WT 
counterparts, nor did they display differences in muscle Akt phosphorylation levels 
(Figure 4.5B-D). These data suggest that insulin resistance is not the cause of muscle 
fatty acid uptake phenotype. However, it is possible that under HFD challenge, the 
reduced fatty acid uptake in LPPARDKO mice may exert protective effects and improve 
insulin sensitivity as a secondary effect (Discussed earlier).  
151
	   	   	   	  
 
 
Figure 4.5. The effects of hepatic PPARδ activity on muscle insulin sensitivity. A. 
C2C12 myotube phospho-Akt levels after insulin stimulation for the indicated time. 
Myotubes were pretreated with vehicle or 50μM of SOPC overnight before being subject 
to 1 hour serum starvation followed by 10nM insulin stimulation. Total Akt levels were 
used as loading control. B. Muscle phospho- and total Akt levels in two month old WT 
and LPPARDKO mice muscle on chow diet around the clock. 3-4 samples were pooled 
for each genotype at each time point. C. and D. Glucose (GTT) (C) and insulin (ITT) (D) 
tolerance test on overnight fasted WT and LPPARDKO mice at 2 month age. 1.5mg/kg 
body weight of glucose and 1U/kg body weight of insulin were used for GTT and ITT, 
respectively. *p<0.05, two-tailed student’s t-test. Value was expressed as mean±SEM. 
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 In light of recent discoveries that intact PCs can act as nuclear receptor ligands, 
we took a candidate approach to hypothesize that SOPC exerts its action through the 
nuclear receptor PPARα. PPARα muscle specific transgenic mice have increased fatty 
acid uptake with elevated muscle CD36 expressions [27], similar to what we saw in 
SOPC treated muscles. In addition, a similar PC species PC(16:0/18:1) was recently 
identified as an endogenous ligand of PPARα in the liver [28]. Gavage of SOPC 
increased muscle fatty acid uptake in WT animals but not in PPARα knockout (PPARα 
KO) mice (Figure 4.6A). Overexpression of PPARδ in WT mice liver induced fatty acid 
uptake in the muscle but not in PPARα KO mice (Figure 4.6B). Stable knockdown of 
PPARα in C2C12 myotubes eliminated the effect of SOPC on fatty acid uptake (Figure 
4.6C). These three lines of evidence strongly support a role of PPARα in mediating the 
effects of SOPC in the muscle.  
 
 
 
 
 
 
 
 
 
 
153
	   	   	   	  
 
Figure 4.6. SOPC promotes muscle fatty acid uptake through PPARα. A. Soleus 
muscle fatty acid uptake in WT and PPARα KO mice 4 hours after gavage of 40mg/kg 
body weight of SOPC with 150 μl of olive oil. Food was removed during the experiment. 
B. Soleus muscle fatty acid uptake in WT and PPARα KO mice 4 days after the tail vein 
injection of GFP or PPARδ adenovirus. C. Ex vivo fatty acid uptake in C2C12 myotubes 
with stable knockdown of PPARα or control. There was no difference in C2C12 
myotubes differentiation between knockdown groups. 50 μM of SOPC or vehicle was 
pretreated to cells overnight before the assay. *p<0.05, two-tailed student’s t-test. Value 
was expressed as mean±SEM. 
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 Is SOPC a ligand of PPARα? Despite strong genetic evidence, we could only 
demonstrate a very modest induction of PPARα activity using the PPARα ligand binding 
domain Gal4 fusion protein (Gal4-PPARα-LBD) in 293 cells. We also could not show a 
strong recruitment of co-activator peptides (data not shown). This perhaps is not 
surprising. As discussed in the previous section, we failed to show the ability of 
PC(16:0/18:1), the putative ligand of PPARα to induce muscle fatty acid uptake, 
whereas the synthetic PPARα ligand Wy14643 is able to induce CD36 expression 
similar to SOPC in C2C12 myotubes (data not shown). These data suggest that the 
synthetic ligand likely does not discriminate the cellular context, while endogenous 
ligands have tissue specific activities. Therefore, 293 cells likely do not share the same 
cellular environment as C2C12 myotubes and are unable to demonstrate the effects of 
SOPC on PPARα activity. To circumvent this issue, we plan to generate stable C2C12 
lines with integrated PPAR response element luciferase (PPRE-luc). Using stable 
C2C12 lines overexpressing an intact or a truncated form of PPARα that is not 
responsive to ligands, we can further evaluate whether the effects on fatty acid uptake is 
dependent on a functional ligand binding domain.  
 Phospholipids undergo extensive modifications in vivo. The presence of 
phospholipases can release fatty acids, lysophosphocholines (LPC), phosphatic acid 
(PA), lysophosphatic acid (LPA) and diacylglycerols (DAG) from PC substrates [14]. 
Each of these breakdown products can act as a signaling molecule. Cellular assays 
mentioned above will not be sufficient to evaluate whether intact SOPC is able to 
activate PPARα.  We plan to determine the binding of SOPC to PPARα biochemically. 
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Using a fluorescent or radiolabelled PPARα liand bound to PPARα-LBD, the 
displacement of fluorescence or radioactivity by cold SOPC will be examined. These 
biochemical assays in cell free environment should address whether SOPC is a PPARα 
ligand. A second possibility is that SOPC acts on upstream signaling pathways that 
converge at PPARα. These effects can be initiated either by intact SOPC via yet 
unknown mechanisms or through its breakdown products, such as DAG, PA, LPA, and 
fatty acids. These products have been linked with Insulin signaling, Src family kinase, 
AMPK, and MAPK pathways. Each of these pathways is capable of modulating PPARα 
activity via direct or indirect mechanisms [29]. We plan to use pathway specific inhibitors 
or activators in C2C12 myotubes to identify candidates for further study.  
 In addition to the candidate approach, unbiased whole transcriptome profiling will 
be helpful not only to elucidate signaling pathways leading to the increased fatty acid 
uptake, but also to identify the full spectrum of actions mediated by SOPC. These goals 
may be achieved by performing in silico analysis of pathway enrichment as well as 
virtual chemical/genetic screen.  
 
Working Model 
 
 Based on the evidence provided in this thesis, we would like to propose a 
working model for the role of hepatic de novo lipogenesis in the regulation of systemic 
metabolic homeostasis (Figure 4.7). The diurnal and/or circadian regulation of hepatic 
lipogenesis in mice is controlled through transcriptional repression via a Rev-erbα/β- 
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HDAC3 complex in the daytime and transcriptional activation by PPARδ at night. 
Elevated PPARδ activity at night is a result of increased gene expression modulated by 
circadian clock machinery and the influx of endogenous ligands that are coupled with 
the feeding cycle. Activation of PPARδ promotes fatty acid synthesis from 
carbohydrates and output of TG/FA and SOPC. Elevated SOPC levels at night facilitate 
TG/fatty acids utilization in the peripheral tissues (e.g. muscle) by activating fatty acids 
utilization genes such as CD36 potentially through nuclear receptor PPARα, therefore 
linking lipid production in the liver to utilization in the muscle. In the absence of hepatic 
PPARδ, the reduced serum SOPC concentration dampens the fatty acid uptake in the 
muscle at the postprandial state. Such reduction under the periodic fasting-feeding cycle 
facilitates excessive glucose utilization and may pose a risk for animals due to 
hypoglycemia. On the contrary, chronic over-nutrition leads to persistent hepatic PPARδ 
activation that eventually exceeds the fatty acid handling capacity of the muscle, 
causing metabolic dysfunction. However, acute induction of hepatic PPARδ activity in 
the insulin resistant state may restore metabolic flexibility by promoting glucose to fatty 
acids conversion and preventing lipotoxicity in the liver. 
 Our study emphasizes a central role of hepatic de novo lipogenesis in modulating 
the fuel selection in peripheral tissues such as the muscle, therefore providing a 
molecular mechanism through which systemic metabolic flexibility is established. 
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Figure 4.7. Working model. 
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